Nephrology Therapeutics
1. Afinitor patent expiration
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of ...
AFINITOR's oppositions filed in EPO
AFINITOR IPR and PTAB Proceedings
Can you believe AFINITOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004973 | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jul, 2016
(9 years ago) | |
| US7741338 | NOVARTIS | Macrolides |
Dec, 2019
(6 years ago) | |
| US8778962 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(3 years ago) | |
| US8436010 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(3 years ago) | |
|
US7297703 (Pediatric) | NOVARTIS | Macrolides |
Jun, 2020
(5 years ago) | |
|
US5665772 (Pediatric) | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Mar, 2020
(5 years ago) | |
| US7297703 | NOVARTIS | Macrolides |
Dec, 2019
(6 years ago) | |
| US5665772 | NOVARTIS | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Sep, 2019
(6 years ago) | |
|
US6004973 (Pediatric) | NOVARTIS | Pharmaceutical compositions comprising rafamycin coprecipitates |
Jan, 2017
(9 years ago) | |
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(2 years from now) | |
|
US8436010 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(3 years ago) | |
|
US8778962 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(3 years ago) | |
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(2 months ago) | |
|
US8410131 (Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-630) | Oct 29, 2013 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-638) | May 05, 2014 |
| New Indication(I-650) | Apr 26, 2015 |
| New Indication(I-655) | Jul 20, 2015 |
| Pediatric Exclusivity(PED) | Apr 29, 2018 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
| New Indication(I-724) | Feb 26, 2019 |
| Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Dosage: TABLET
How can I launch a generic of AFINITOR before it's drug patent expiration?
More Information on Dosage
AFINITOR family patents
2. Agamree patent expiration
Treatment: Treatment of duchenne muscular dystrophy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12201639 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Mar, 2040
(14 years from now) | |
| US11382922 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Jul, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690853 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
Mar, 2033
(7 years from now) | |
| US11471471 | CATALYST PHARMS | Aqueous oral pharmaceutical suspension compositions |
Mar, 2040
(14 years from now) | |
| US10857161 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(3 years from now) | |
| US8334279 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-κB for treatment of disease |
May, 2029
(3 years from now) | |
| US11833159 | CATALYST PHARMS | Non-hormonal steroid modulators of NF-kB for treatment of disease |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2028 |
| Orphan Drug Exclusivity(ODE-450) | Oct 26, 2030 |
Drugs and Companies using VAMOROLONE ingredient
NCE-1 date: 27 October, 2027
Market Authorisation Date: 26 October, 2023
Dosage: SUSPENSION
More Information on Dosage
AGAMREE family patents
3. Amondys 45 patent
expiration
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein prod...
AMONDYS 45's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524880 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Apr, 2026
(2 months from now) | |
| US9416361 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| USRE48960 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Feb, 2029
(3 years from now) | |
| US10287586 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(4 years from now) | |
| US9447415 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US9228187 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533174 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US9758783 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(4 years from now) | |
| US10781450 | SAREPTA THERAPS INC | Antisense molecules and methods for treating pathologies |
Nov, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2026 |
| Orphan Drug Exclusivity(ODE-347) | Feb 25, 2028 |
Drugs and Companies using CASIMERSEN ingredient
NCE-1 date: 25 February, 2025
Market Authorisation Date: 25 February, 2021
Dosage: SOLUTION
More Information on Dosage
AMONDYS 45 family patents
4. Ampyra patent expiration
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
AMPYRA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9918973 | MERZ | Sustained release aminopyridine composition |
Dec, 2024
(1 year, 1 month ago) | |
| US8663685 | MERZ | Sustained release aminopyridine composition |
Jan, 2025
(11 months ago) | |
| US8440703 | MERZ | Methods of using sustained release aminopyridine compositions |
Apr, 2025
(9 months ago) | |
| US8354437 | MERZ | Method of using sustained release aminopyridine compositions |
Dec, 2026
(11 months from now) | |
| US5540938 | MERZ | Formulations and their use in the treatment of neurological diseases |
Jul, 2018
(7 years ago) | |
| US8007826 | MERZ | Sustained release aminopyridine composition |
May, 2027
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
Drugs and Companies using DALFAMPRIDINE ingredient
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage
AMPYRA family patents
5. Amvuttra patent expiration
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
AMVUTTRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9399775 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(6 years from now) | |
| US11286486 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US10683501 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US9370581 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(2 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(3 years from now) | |
| US10612024 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(9 years from now) | |
| US10208307 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US12049628 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(10 years from now) | |
| US10570391 | ALNYLAM PHARMS INC | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
Nov, 2032
(6 years from now) | |
| US11401517 | ALNYLAM PHARMS INC | Modified double-stranded RNA agents |
Aug, 2035
(9 years from now) | |
| US10806791 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 13, 2027 |
| New Indication(I-964) | Mar 20, 2028 |
| Orphan Drug Exclusivity(ODE-212) | Jun 13, 2029 |
Drugs and Companies using VUTRISIRAN SODIUM ingredient
NCE-1 date: 13 June, 2026
Market Authorisation Date: 13 June, 2022
Dosage: SOLUTION
More Information on Dosage
AMVUTTRA family patents
6. Amyvid patent expiration
Treatment: Pet to estimate amyloid beta neuritic plaque density in adults with cognitive impairment: -evaluation of alzheimer’s disease and other causes of cognitive decline -selection of patients who are indica...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7687052 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(1 year, 3 months from now) | |
| US8506929 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2017 |
Drugs and Companies using FLORBETAPIR F-18 ingredient
NCE-1 date: 06 April, 2016
Market Authorisation Date: 06 April, 2012
Dosage: SOLUTION
More Information on Dosage
AMYVID family patents
7. Aptiom patent expiration
Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with ...
APTIOM's oppositions filed in EPO
Can you believe APTIOM received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5753646 | SUMITOMO PHARMA AM | Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
Jun, 2021
(4 years ago) | |
| US9206135 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750747 | SUMITOMO PHARMA AM | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(6 years from now) | |
| US9763954 | SUMITOMO PHARMA AM | Therapeutical uses of eslicarbazepine |
Sep, 2028
(2 years from now) | |
| US10702536 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US11364247 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US9643929 | SUMITOMO PHARMA AM | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(3 months from now) | |
| US10695354 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US10912781 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(2 years from now) | |
| US10675287 | SUMITOMO PHARMA AM | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(8 months ago) | |
| US8372431 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(4 years from now) | |
| US9566244 | SUMITOMO PHARMA AM | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-150) | Aug 27, 2018 |
| New Indication(I-715) | Aug 27, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2018 |
Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient
NCE-1 date: 08 November, 2017
Market Authorisation Date: 08 November, 2013
Dosage: TABLET
How can I launch a generic of APTIOM before it's drug patent expiration?
More Information on Dosage
APTIOM family patents
8. Aqneursa patent expiration
Treatment: Treatment of neurological manifestations of niemann-pick disease type-c (npc) for a duration of greater than 3 months; Use of levacetylleucine for treatment of neurological manifestations of niemann-p...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12433862 | INTRABIO | NA |
Apr, 2037
(11 years from now) | |
| US11400067 | INTRABIO | Pharmaceutical compositions and uses directed to lysosomal storage disorders |
Apr, 2037
(11 years from now) | |
| US12433863 | INTRABIO | NA |
Apr, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 24, 2029 |
| Orphan Drug Exclusivity(ODE-498) | Sep 24, 2031 |
Drugs and Companies using LEVACETYLLEUCINE ingredient
NCE-1 date: 24 September, 2028
Market Authorisation Date: 24 September, 2024
Dosage: FOR SUSPENSION
More Information on Dosage
AQNEURSA family patents
9. Aubagio patent expiration
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction...
AUBAGIO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5679709 | SANOFI AVENTIS US | Medicaments to combat autoimmune diseases |
Oct, 2014
(11 years ago) | |
| US5459163 | SANOFI AVENTIS US | Medicament to combat autoimmune diseases |
Oct, 2012
(13 years ago) | |
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(8 years from now) | |
| US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(7 months from now) | |
| US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(4 years from now) | |
|
US8802735 (Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(5 years from now) | |
|
US6794410 (Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(1 year, 1 month from now) | |
|
US9186346 (Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Dosage: TABLET
How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage
AUBAGIO family patents
10. Austedo patent expiration
Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia
AUSTEDO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9550780 | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10959996 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11564917 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US12016858 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11648244 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11357772 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11813232 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(12 years from now) | |
| US9233959 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US11179386 | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(12 years from now) | |
| US9814708 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US9296739 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US11446291 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(10 years from now) | |
| US11666566 | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
|
US9233959 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US8524733 (Pediatric) | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(5 years from now) | |
|
US9296739 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US9550780 (Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US9814708 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US11813232 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(12 years from now) | |
|
US10959996 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11564917 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11179386 (Pediatric) | TEVA BRANDED PHARM | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(12 years from now) | |
|
US11666566 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(8 years from now) | |
|
US11648244 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11446291 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11357772 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US12016858 (Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-751) | Aug 30, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
| Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
| M(M-54) | Jun 24, 2024 |
| Pediatric Exclusivity(PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Dosage: TABLET
How can I launch a generic of AUSTEDO before it's drug patent expiration?
More Information on Dosage
AUSTEDO family patents
11. Avodart patent expiration
Treatment: Method of inhibiting 5 alpha testosterone reductase enzyme with dutasteride or its derivative and treating androgen responsive/mediated disease including benign prostatic hyperplasia; Method of treati...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5998427 | WAYLIS THERAP | Androstenones |
Sep, 2013
(12 years ago) | |
| US5846976 | WAYLIS THERAP | Androstenone derivative |
Sep, 2013
(12 years ago) | |
| US5565467 | WAYLIS THERAP | Androstenone derivative |
Nov, 2015
(10 years ago) | |
Drugs and Companies using DUTASTERIDE ingredient
Market Authorisation Date: 20 November, 2001
Dosage: CAPSULE
How can I launch a generic of AVODART before it's drug patent expiration?
More Information on Dosage
AVODART family patents
12. Axert patent expiration
Treatment: Treatment of migraine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5565447 (Pediatric) | JANSSEN PHARMS | Indole derivatives |
Nov, 2015
(10 years ago) | |
| US5565447 | JANSSEN PHARMS | Indole derivatives |
May, 2015
(10 years ago) | |
Drugs and Companies using ALMOTRIPTAN MALATE ingredient
Market Authorisation Date: 07 May, 2001
Dosage: TABLET
How can I launch a generic of AXERT before it's drug patent expiration?
More Information on Dosage
AXERT family patents
13. Azilect patent expiration
Treatment: Treatment of parkinson's disease
AZILECT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7815942 | TEVA | Rasagiline formulations of improved content uniformity |
Aug, 2027
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5453446 | TEVA | Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease. |
Feb, 2017
(8 years ago) | |
| US6126968 | TEVA | Stable compositions containing N-propargyl-1-aminoindan |
Sep, 2016
(9 years ago) | |
| US5532415 | TEVA | R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof |
Jul, 2013
(12 years ago) | |
| US7572834 | TEVA | Rasagiline formulations and processes for their preparation |
Dec, 2026
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-685) | May 29, 2017 |
Drugs and Companies using RASAGILINE MESYLATE ingredient
Market Authorisation Date: 16 May, 2006
Dosage: TABLET
More Information on Dosage
AZILECT family patents
14. Belsomra patent expiration
Treatment: Treatment of insomnia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7951797 | MERCK SHARP DOHME | Substituted diazepan orexin receptor antagonists |
Nov, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11980623 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(7 years from now) | |
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2019 |
| M(M-253) | Jan 29, 2023 |
Drugs and Companies using SUVOREXANT ingredient
NCE-1 date: 13 August, 2018
Market Authorisation Date: 13 August, 2014
Dosage: TABLET
More Information on Dosage
BELSOMRA family patents
15. Blujepa patent expiration
Treatment: Treatment of adult and pediatric patients 12 years of age and older weighing at least 45 kg who have limited or no alternative options with uncomplicated urogenital gonorrhea caused by susceptible str...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8389524 | GLAXOSMITHKLINE | Tricyclic nitrogen containing compounds as antibacterial agents |
Feb, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702521 | GLAXOSMITHKLINE | NA |
Aug, 2035
(9 years from now) | |
| US11229646 | GLAXOSMITHKLINE | NA |
Aug, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-978) | Dec 11, 2028 |
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 25, 2035 |
Drugs and Companies using GEPOTIDACIN MESYLATE ingredient
NCE-1 date: 25 March, 2034
Market Authorisation Date: 25 March, 2025
Dosage: TABLET
More Information on Dosage
BLUJEPA family patents
16. Briviact patent expiration
Treatment: Treatment of partial-onset seizures in patients 4 years of age and older; Treatment of partial onset seizures in patients with epilepsy aged 16 years and older with epilepsy
BRIVIACT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6784197 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2021
(4 years ago) | |
| US6911461 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2026
(a month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8492416 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2021
(4 years ago) | |
| US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 12, 2021 |
| New Patient Population(NPP) | Aug 27, 2024 |
Drugs and Companies using BRIVARACETAM ingredient
NCE-1 date: 12 May, 2020
Market Authorisation Date: 12 May, 2016
Dosage: TABLET; SOLUTION
How can I launch a generic of BRIVIACT before it's drug patent expiration?
More Information on Dosage
BRIVIACT family patents
17. Cabometyx patent expiration
Treatment: Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy; Treatment of advanced renal cell carcinoma; Treatment of previously treated, unresectable,...
CABOMETYX's oppositions filed in EPO
CABOMETYX IPR and PTAB Proceedings
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8877776 | EXELIXIS INC | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(4 years from now) | |
| US7579473 | EXELIXIS INC | c-Met modulators and methods of use |
Aug, 2026
(6 months from now) | |
| US11091439 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11141413 | EXELIXIS INC | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
Apr, 2037
(11 years from now) | |
| US8497284 | EXELIXIS INC | C-met modulators and method of use |
Sep, 2024
(1 year, 3 months ago) | |
| US12128039 | EXELIXIS INC | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(6 years from now) | |
| US10034873 | EXELIXIS INC | C-met modulator pharmaceutical compositions |
Jul, 2031
(5 years from now) | |
| US10039757 | EXELIXIS INC | C-Met modulator pharmaceutical compositions |
Jul, 2031
(5 years from now) | |
| US11098015 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(4 years from now) | |
| US9724342 | EXELIXIS INC | C-met modulator pharmaceutical compositions |
Jul, 2033
(7 years from now) | |
| US11298349 | EXELIXIS INC | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(6 years from now) | |
| US11091440 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-760) | Dec 19, 2020 |
| New Indication(I-792) | Jan 14, 2022 |
| New Indication(I-854) | Jan 22, 2024 |
| New Indication(I-873) | Sep 17, 2024 |
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Dosage: TABLET
How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage
CABOMETYX family patents
18. Cialis patent expiration
Treatment: Erectile dysfunction; Treatment of erectile dysfunction; Treatment of sexual dysfunction
CIALIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6943166 (Pediatric) | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Oct, 2020
(5 years ago) | |
| US6821975 | LILLY | Beta-carboline drug products |
Nov, 2020
(5 years ago) | |
| US6140329 | LILLY | Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence |
Jul, 2016
(9 years ago) | |
| US7182958 | LILLY | β-carboline pharmaceutical compositions |
Apr, 2020
(5 years ago) | |
|
US5859006 (Pediatric) | LILLY | Tetracyclic derivatives; process of preparation and use |
May, 2018
(7 years ago) | |
|
US6821975 (Pediatric) | LILLY | Beta-carboline drug products |
May, 2021
(4 years ago) | |
| US5859006 | LILLY | Tetracyclic derivatives; process of preparation and use |
Nov, 2017
(8 years ago) | |
|
US7182958 (Pediatric) | LILLY | β-carboline pharmaceutical compositions |
Oct, 2020
(5 years ago) | |
| US6943166 | LILLY | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
Apr, 2020
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-641) | Oct 06, 2014 |
| New Indication(I-642) | Oct 06, 2014 |
| M(M-219) | Feb 15, 2021 |
| Pediatric Exclusivity(PED) | Aug 15, 2021 |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 07 January, 2008
Dosage: TABLET
How can I launch a generic of CIALIS before it's drug patent expiration?
More Information on Dosage
CIALIS family patents
19. Cometriq patent expiration
Treatment: Method of treating medullary thyroid cancer
COMETRIQ's oppositions filed in EPO
COMETRIQ IPR and PTAB Proceedings
Can you believe COMETRIQ received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8877776 | EXELIXIS | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(4 years from now) | |
| US7579473 | EXELIXIS | c-Met modulators and methods of use |
Aug, 2026
(6 months from now) | |
| US11091439 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12128039 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(6 years from now) | |
| US11091440 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(4 years from now) | |
| US11098015 | EXELIXIS | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(4 years from now) | |
| US11298349 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(6 years from now) | |
| US9717720 | EXELIXIS | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| Orphan Drug Exclusivity(ODE) | Nov 29, 2019 |
| Orphan Drug Exclusivity(ODE-33) | Nov 29, 2019 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 29 November, 2012
Dosage: CAPSULE
More Information on Dosage
COMETRIQ family patents
20. Comtan patent expiration
Treatment: Treatment of parkinson's disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5446194 | ORION PHARMA | Pharmacologically active catechol derivatives |
Oct, 2013
(12 years ago) | |
| US6599530 | ORION PHARMA | Oral compacted composition comprising catechol derivatives |
Sep, 2018
(7 years ago) | |
Drugs and Companies using ENTACAPONE ingredient
Market Authorisation Date: 19 October, 1999
Dosage: TABLET
How can I launch a generic of COMTAN before it's drug patent expiration?
More Information on Dosage
COMTAN family patents
21. Crenessity patent expiration
Treatment: Adjunctive treatment of classic congenital adrenal hyperplasia (cah)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12128033 | NEUROCRINE | Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine |
Jun, 2041
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10905690 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11311544 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| US11730739 | NEUROCRINE | Treatment of congenital adrenal hyperplasia |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2029 |
| Orphan Drug Exclusivity(ODE-503) | Dec 13, 2031 |
Drugs and Companies using CRINECERFONT ingredient
NCE-1 date: 13 December, 2028
Market Authorisation Date: 13 December, 2024
Dosage: CAPSULE; SOLUTION
More Information on Dosage
CRENESSITY family patents
22. Cymbalta patent expiration
Treatment: Management of fibromyalgia (fm); Method of treating anxiety
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6596756 (Pediatric) | LILLY | Treatment of fibromyalgia |
Mar, 2020
(5 years ago) | |
| US5508276 | LILLY | Duloxetine enteric pellets |
Jul, 2014
(11 years ago) | |
| US6596756 | LILLY | Treatment of fibromyalgia |
Sep, 2019
(6 years ago) | |
| US5023269 | LILLY | 3-aryloxy-3-substituted propanamines |
Jun, 2013
(12 years ago) | |
|
US5023269 (Pediatric) | LILLY | 3-aryloxy-3-substituted propanamines |
Dec, 2013
(12 years ago) | |
|
US5508276 (Pediatric) | LILLY | Duloxetine enteric pellets |
Jan, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-617) | Nov 19, 2012 |
| New Indication(I-632) | Nov 04, 2013 |
| Pediatric Exclusivity(PED) | Apr 18, 2016 |
| M(M-61) | Oct 18, 2015 |
| New Patient Population(NPP) | Apr 20, 2023 |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 August, 2004
Dosage: CAPSULE, DELAYED REL PELLETS
How can I launch a generic of CYMBALTA before it's drug patent expiration?
More Information on Dosage
CYMBALTA family patents
23. Daybue patent expiration
Treatment: Treatment of rett syndrome or a symptom thereof
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11827600 | ACADIA PHARMS INC | Crystalline forms of trofinetide |
Jul, 2042
(16 years from now) | |
| US11370755 | ACADIA PHARMS INC | Compositions of trofinetide |
Aug, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9212204 | ACADIA PHARMS INC | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid |
Jan, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2028 |
| Orphan Drug Exclusivity(ODE-425) | Mar 10, 2030 |
Drugs and Companies using TROFINETIDE ingredient
NCE-1 date: 11 March, 2027
Market Authorisation Date: 10 March, 2023
Dosage: SOLUTION
More Information on Dosage
DAYBUE family patents
24. Dayvigo patent expiration
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8268848 | EISAI INC | Cyclopropane compound |
Sep, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188652 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(9 years from now) | |
| US11026944 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(9 years from now) | |
| US10702529 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2025 |
| M(M-293) | Apr 20, 2026 |
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: 07 April, 2024
Market Authorisation Date: 07 April, 2020
Dosage: TABLET
More Information on Dosage
DAYVIGO family patents
25. Doribax patent expiration
Treatment: Method of treating bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8247402 | SHIONOGI INC | Crystal form of pyrrolidylthiocarbapenem derivative |
Mar, 2021
(4 years ago) | |
| US5317016 | SHIONOGI INC | Pyrrolidylthiocarbapenem derivative |
Jun, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
Drugs and Companies using DORIPENEM ingredient
NCE-1 date: 13 October, 2011
Market Authorisation Date: 05 October, 2010
Dosage: INJECTABLE
How can I launch a generic of DORIBAX before it's drug patent expiration?
More Information on Dosage
DORIBAX family patents
26. Duvyzat patent expiration
Treatment: A method for the treatment of duchenne muscular dystrophy (dmd) using givinostat
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7329689 | ITALFARMACO SPA | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
Jan, 2026
(a day from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9421184 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(6 years from now) | |
| US9867799 | ITALFARMACO SPA | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
Feb, 2032
(6 years from now) | |
| US10688047 | ITALFARMACO SPA | Physically and chemically stable oral suspensions of givinostat |
Oct, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2029 |
| Orphan Drug Exclusivity(ODE-473) | Mar 21, 2031 |
Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient
NCE-1 date: 21 March, 2028
Market Authorisation Date: 21 March, 2024
Dosage: SUSPENSION
More Information on Dosage
DUVYZAT family patents
27. Enablex patent expiration
Treatment: Treating urinary incontinence by administering an extended-release form of darifenacin; Treating a disease of altered motility or tone of smooth muscle by administering a muscarinic receptor antagoniz...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6106864 | ABBVIE | Pharmaceutical formulations containing darifenacin |
Aug, 2016
(9 years ago) | |
| US5096890 | ABBVIE | Pyrrolidine derivatives |
Mar, 2015
(10 years ago) | |
Drugs and Companies using DARIFENACIN HYDROBROMIDE ingredient
Market Authorisation Date: 22 December, 2004
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ENABLEX before it's drug patent expiration?
More Information on Dosage
ENABLEX family patents
28. Epidiolex patent expiration
Treatment: Use for the treatment of focal seizures in patients with dravet syndrome; Use for reducing convulsive seizure frequency in patients with dravet syndrome; Use for the treatment of atonic seizures in pa...
EPIDIOLEX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10195159 | JAZZ PHARMS RES | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
May, 2022
(3 years ago) | |
| US11207292 | JAZZ PHARMS RES | Cannabidiol preparations and its uses |
Apr, 2039
(13 years from now) | |
| US11096905 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Oct, 2035
(9 years from now) | |
| US11865102 | JAZZ PHARMS RES | Cannabidiol preparations and its uses |
Apr, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11357741 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10603288 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10111840 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US9956183 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US9956184 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11963937 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US9956185 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US12064399 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11766411 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11065209 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(9 years from now) | |
| US11160795 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(15 years from now) | |
| US11154516 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10849860 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10918608 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(9 years from now) | |
| US10966939 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11406623 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(15 years from now) | |
| US11701330 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US9956186 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10092525 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US9949937 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11633369 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10709671 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10137095 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US12102619 | JAZZ PHARMS RES | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
Mar, 2041
(15 years from now) | |
| US10709674 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11311498 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US11400055 | JAZZ PHARMS RES | Use of cannabidiol in the treatment of epilepsy |
Oct, 2035
(9 years from now) | |
| US11446258 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| US10709673 | JAZZ PHARMS RES | Use of cannabinoids in the treatment of epilepsy |
Jun, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 31, 2023 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-216) | Sep 28, 2025 |
| M(M-270) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-326) | Jul 31, 2027 |
| Orphan Drug Exclusivity(ODE-332) | Jul 31, 2027 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: 28 September, 2022
Market Authorisation Date: 28 September, 2018
Dosage: SOLUTION
How can I launch a generic of EPIDIOLEX before it's drug patent expiration?
More Information on Dosage
EPIDIOLEX family patents
29. Evrysdi patent expiration
Treatment: Treatment of spinal muscular atrophy
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(9 years from now) | |
| US12122789 | GENENTECH INC | Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making |
Apr, 2041
(15 years from now) | |
| US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350273 | GENENTECH INC | NA |
Oct, 2038
(12 years from now) | |
| US11534444 | GENENTECH INC | Treatment of SMA |
Oct, 2038
(12 years from now) | |
| US11827646 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Jan, 2036
(10 years from now) | |
| US11938136 | GENENTECH INC | Compositions for treating spinal muscular atrophy |
Nov, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 07, 2025 |
| M(M-270) | Oct 03, 2026 |
| Orphan Drug Exclusivity(ODE-334) | Aug 07, 2027 |
| Orphan Drug Exclusivity(ODE-400) | May 27, 2029 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 07 August, 2024
Market Authorisation Date: 11 February, 2025
Dosage: TABLET; FOR SOLUTION
More Information on Dosage
EVRYSDI family patents
30. Exelon patent expiration
Treatment: Treatment of alzheimer's dementia
EXELON IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6316023 | SANDOZ | TTS containing an antioxidant |
Jan, 2019
(7 years ago) | |
| US6335031 | SANDOZ | TTS containing an antioxidant |
Jan, 2019
(7 years ago) | |
| US4948807 | SANDOZ | Phenyl carbamates |
Aug, 2012
(13 years ago) | |
| US5602176 | SANDOZ | Phenyl carbamate |
Feb, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 31, 2015 |
| New Patient Population(NPP) | Jun 27, 2016 |
Drugs and Companies using RIVASTIGMINE ingredient
Market Authorisation Date: 06 July, 2007
Dosage: FILM, EXTENDED RELEASE
How can I launch a generic of EXELON before it's drug patent expiration?
More Information on Dosage
EXELON family patents
31. Exelon patent expiration
Treatment: Treatment of alzheimer's dementia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US4948807 | NOVARTIS | Phenyl carbamates |
Aug, 2012
(13 years ago) | |
| US5602176 | NOVARTIS | Phenyl carbamate |
Feb, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 31, 2015 |
| New Patient Population(NPP) | Jun 27, 2016 |
Drugs and Companies using RIVASTIGMINE TARTRATE ingredient
Market Authorisation Date: 21 April, 2000
Dosage: CAPSULE; SOLUTION
How can I launch a generic of EXELON before it's drug patent expiration?
More Information on Dosage
EXELON family patents
32. Exondys 51 patent expiration
Treatment: (i)treatment of duchenne muscular dystrophy; (ii)restoring/increasing functional dystrophin protein; Or (iii) inducing skipping; Each of (i)-(iii) in patients having a confirmed mutation of the dmd ge...
EXONDYS 51's oppositions filed in EPO
EXONDYS 51 IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416361 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US9243245 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(2 years from now) | |
| US9018368 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US10781451 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8486907 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US10533174 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10364431 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(8 years from now) | |
| USRE47751 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US9506058 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(8 years from now) | |
| US10337003 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(8 years from now) | |
| USRE48468 | SAREPTA THERAPS INC | Means and methods for counteracting muscle disorders |
Oct, 2028
(2 years from now) | |
| USRE47769 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Feb, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Sep 19, 2023 |
| Orphan Drug Exclusivity(ODE-122) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
NCE-1 date: 19 September, 2020
Market Authorisation Date: 19 September, 2016
Dosage: SOLUTION
More Information on Dosage
EXONDYS 51 family patents
33. Extraneal patent expiration
Treatment: Peritoneal dialysis solution
EXTRANEAL IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6077836 | VANTIVE US HLTHCARE | Peritoneal dialysis and compositions for use therein |
Jun, 2017
(8 years ago) | |
| US6248726 | VANTIVE US HLTHCARE | Method of peritoneal dialysis using glucose polymer solutions |
Jun, 2018
(7 years ago) | |
Drugs and Companies using ICODEXTRIN ingredient
Market Authorisation Date: 20 December, 2002
Dosage: SOLUTION
More Information on Dosage
EXTRANEAL family patents
34. Feraheme patent expiration
Treatment: Method of treating patients needing an iron supplement
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8926947 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501158 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(5 years ago) | |
| US8591864 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(5 years ago) | |
| US6599498 | COVIS | Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives |
Mar, 2020
(5 years ago) | |
| US7553479 | COVIS | Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof |
Mar, 2020
(5 years ago) | |
| US7871597 | COVIS | Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
Mar, 2020
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 30, 2012 |
| New Indication(I-767) | Feb 02, 2021 |
Drugs and Companies using FERUMOXYTOL ingredient
Market Authorisation Date: 30 June, 2009
Dosage: SOLUTION
How can I launch a generic of FERAHEME before it's drug patent expiration?
More Information on Dosage
FERAHEME family patents
35. Fetroja patent expiration
Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI INC | Cephalosporin having catechol group |
Nov, 2033
(7 years from now) | |
| US10004750 | SHIONOGI INC | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI INC | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-844) | Sep 25, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 14 November, 2028
Market Authorisation Date: 14 November, 2019
Dosage: POWDER
More Information on Dosage
FETROJA family patents
36. Filspari patent expiration
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk for disease progression
FILSPARI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993461 | TRAVERE | Method for treating disorders associated with glomerular function |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2028 |
| Orphan Drug Exclusivity(ODE-389) | Feb 17, 2030 |
| Orphan Drug Exclusivity(ODE-493) | Sep 05, 2031 |
Drugs and Companies using SPARSENTAN ingredient
NCE-1 date: 17 February, 2027
Market Authorisation Date: 17 February, 2023
Dosage: TABLET
More Information on Dosage
FILSPARI family patents
37. Fintepla patent expiration
Treatment: Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution; Use in combination with stiripento...
FINTEPLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10947183 | UCB INC | Fenfluramine compositions and methods of preparing the same |
Dec, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10950331 | UCB INC | Control system for control of distribution of medication |
Sep, 2035
(9 years from now) | |
|
US10947183 (Pediatric) | UCB INC | Fenfluramine compositions and methods of preparing the same |
Jun, 2037
(11 years from now) | |
|
US10950331 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Mar, 2036
(10 years from now) | |
|
US9610260 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(7 years from now) | |
|
US10478442 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(7 years from now) | |
|
US10478441 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(7 years from now) | |
| US9603814 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(7 years from now) | |
| US10478441 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(7 years from now) | |
| US12097206 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(7 years from now) | |
| US11406606 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(11 years from now) | |
| US9603815 | UCB INC | Method for the treatment of Dravet syndrome |
May, 2033
(7 years from now) | |
| US9549909 | UCB INC | Method for the treatment of dravet syndrome |
May, 2033
(7 years from now) | |
| US10452815 | UCB INC | Control system for control of distribution of medication |
Jun, 2038
(12 years from now) | |
| US9610260 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(7 years from now) | |
| US10478442 | UCB INC | Method for the treatment of Dravet Syndrome |
May, 2033
(7 years from now) | |
| US10603290 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(11 years from now) | |
| US11040018 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(11 years from now) | |
| US11759440 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(11 years from now) | |
| US11786487 | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(11 years from now) | |
|
US11759440 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(12 years from now) | |
|
US11406606 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(12 years from now) | |
|
US9603815 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(7 years from now) | |
|
US9549909 (Pediatric) | UCB INC | Method for the treatment of dravet syndrome |
Nov, 2033
(7 years from now) | |
|
US10452815 (Pediatric) | UCB INC | Control system for control of distribution of medication |
Dec, 2038
(12 years from now) | |
|
US9603814 (Pediatric) | UCB INC | Method for the treatment of Dravet syndrome |
Nov, 2033
(7 years from now) | |
|
US10603290 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(12 years from now) | |
|
US11040018 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(12 years from now) | |
|
US12097206 (Pediatric) | UCB INC | Method for the treatment of Dravet Syndrome |
Nov, 2033
(7 years from now) | |
|
US11786487 (Pediatric) | UCB INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Feb, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 25, 2023 |
| New Indication(I-887) | Mar 25, 2025 |
| Orphan Drug Exclusivity(ODE-312) | Jun 25, 2027 |
| Orphan Drug Exclusivity(ODE-393) | Mar 25, 2029 |
| Pediatric Exclusivity(PED) | Sep 25, 2029 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Dosage: SOLUTION
How can I launch a generic of FINTEPLA before it's drug patent expiration?
More Information on Dosage
FINTEPLA family patents
38. Firdapse patent expiration
Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11274332 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(6 years from now) | |
| US11274331 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(6 years from now) | |
| US11268128 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(6 years from now) | |
| US11060128 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(6 years from now) | |
| US10793893 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
May, 2034
(8 years from now) | |
| US10626088 | CATALYST PHARMS | Determining degradation of 3,4-diaminopyridine |
Feb, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
| New Patient Population(NPP) | Sep 29, 2025 |
| Orphan Drug Exclusivity(ODE-223) | Nov 28, 2025 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Dosage: TABLET
How can I launch a generic of FIRDAPSE before it's drug patent expiration?
More Information on Dosage
FIRDAPSE family patents
39. Forzinity patent expiration
Treatment: Method for treating barth syndrome in adult and pediatric patients weighing at least 30kg
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7576061 | STEALTH BIOTHERAPS | NA |
Jan, 2026
(6 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12268724 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US11771734 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US11083772 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US11083771 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| US9687519 | STEALTH BIOTHERAPS | NA |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2030 |
Drugs and Companies using ELAMIPRETIDE HYDROCHLORIDE ingredient
NCE-1 date: 19 September, 2029
Market Authorisation Date: 19 September, 2025
Dosage: SOLUTION
More Information on Dosage
FORZINITY family patents
40. Fosrenol patent expiration
Treatment: Reduction of serum phosphate; Reduction of serum phosphate in patients with end stage renal disease
FOSRENOL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5968976 | TAKEDA PHARMS USA | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
Oct, 2018
(7 years ago) | |
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(1 year, 4 months ago) | |
| US7465465 | TAKEDA PHARMS USA | Pharmaceutical formulation comprising lanthanum compounds |
Aug, 2024
(1 year, 4 months ago) | |
| US8980327 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(4 years from now) | |
| US9023397 | TAKEDA PHARMS USA | Capsule and powder formulations containing lanthanum compounds |
Dec, 2030
(4 years from now) | |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 26 October, 2004
Dosage: POWDER; TABLET, CHEWABLE
How can I launch a generic of FOSRENOL before it's drug patent expiration?
More Information on Dosage
FOSRENOL family patents
41. Fotivda patent expiration
Treatment: Treatment of adults with moderate hepatic impairment and relapsed or refractory advanced renal cell carcinoma following two or more prior systemic anti-cancer therapies with 1mg tivozanib hcl orally f...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6821987 | AVEO PHARMS | Quinoline derivatives and quinazoline derivatives having azolyl group |
Apr, 2025
(8 months ago) | |
| US7166722 | AVEO PHARMS | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
Nov, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11504365 | AVEO PHARMS | Use of tivozanib to treat subjects with refractory cancer |
Nov, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2025
Market Authorisation Date: 10 March, 2021
Dosage: CAPSULE
More Information on Dosage
FOTIVDA family patents
42. Frova patent expiration
Treatment: Acute treatment of migraine attacks with or without aura in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5464864 | ENDO OPERATIONS | Use of tetrahydrocarbazone derivatives as 5HT1 receptor agonists |
Nov, 2015
(10 years ago) | |
| US5616603 | ENDO OPERATIONS | Enantiomers of carbazole derivatives as 5-HT1 -like agonists |
Apr, 2014
(11 years ago) | |
| US5637611 | ENDO OPERATIONS | Medicaments |
Jun, 2014
(11 years ago) | |
| US5827871 | ENDO OPERATIONS | Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT1 agonist use thereof |
Oct, 2015
(10 years ago) | |
| US5962501 | ENDO OPERATIONS | Enantiomer of carbazole derivative as 5-HT1-like agonists |
Dec, 2013
(12 years ago) | |
Drugs and Companies using FROVATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 08 November, 2001
Dosage: TABLET
How can I launch a generic of FROVA before it's drug patent expiration?
More Information on Dosage
FROVA family patents
43. Gemtesa patent expiration
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (bph); Treat...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8653260 | SUMITOMO PHARMA AM | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
Apr, 2029
(3 years from now) | |
| US8247415 | SUMITOMO PHARMA AM | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2034
(8 years from now) | |
| US12180219 | SUMITOMO PHARMA AM | Process for preparing beta 3 agonists and intermediates |
Mar, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12357636 | SUMITOMO PHARMA AM | NA |
Jul, 2042
(16 years from now) | |
| US12102638 | SUMITOMO PHARMA AM | Use of vibegron to treat overactive bladder |
Mar, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2025 |
| New Indication(I-955) | Dec 18, 2027 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 23 December, 2024
Market Authorisation Date: 23 December, 2020
Dosage: TABLET
More Information on Dosage
GEMTESA family patents
44. Gilenya patent expiration
Treatment: Treatment of autoimmune disease; Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; Treatment of mult...
GILENYA's oppositions filed in EPO
GILENYA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2019
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004565 | NOVARTIS | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
Sep, 2017
(8 years ago) | |
|
US5604229 (Pediatric) | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Aug, 2019
(6 years ago) | |
| US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2014
(11 years ago) | |
| US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(1 year, 11 months from now) | |
| US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(6 years from now) | |
| US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(1 year, 5 months from now) | |
| US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(2 months from now) | |
|
US8324283 (Pediatric) | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Sep, 2026
(8 months from now) | |
|
US9187405 (Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(1 year, 11 months from now) | |
|
US9592208 (Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-106) | Jul 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
| New Patient Population(NPP) | May 11, 2021 |
| New Strength(NS) | May 11, 2021 |
| Pediatric Exclusivity(PED) | Nov 11, 2021 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Dosage: CAPSULE
How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage
GILENYA family patents
45. Hetlioz patent expiration
Treatment: Treatment of non-24-hour sleep-wake disorder; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon; Treatment of non-24-hour sleep-wake disorder by avoiding...
HETLIOZ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(3 years ago) | |
| US11566011 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(9 years from now) | |
| US12049457 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(9 years from now) | |
| US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(9 years from now) | |
| US11760740 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(9 years from now) | |
| US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785492 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11633377 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US9060995 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(8 years from now) | |
| US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(9 years from now) | |
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US12201604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US9855241 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| USRE46604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(8 years from now) | |
| US11759446 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Feb, 2041
(15 years from now) | |
| US10449176 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(8 years from now) | |
| US9549913 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11266622 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(9 years from now) | |
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(9 years from now) | |
| US10945988 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11786502 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(8 years from now) | |
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11850229 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11833130 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11918557 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| US11918556 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Apr, 2033
(7 years from now) | |
| US11826339 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2021 |
| Orphan Drug Exclusivity(ODE-59) | Jan 31, 2021 |
| New Indication(I-850) | Dec 01, 2023 |
| Orphan Drug Exclusivity(ODE-330) | Dec 01, 2027 |
Drugs and Companies using TASIMELTEON ingredient
NCE-1 date: 31 January, 2018
Market Authorisation Date: 31 January, 2014
Dosage: CAPSULE
How can I launch a generic of HETLIOZ before it's drug patent expiration?
More Information on Dosage
HETLIOZ family patents
46. Horizant patent expiration
Treatment: Management of postherpetic neuralgia (phn) in adults; Treatment of moderate-to-severe primary restless leg syndrome in adults
HORIZANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6818787 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(9 months ago) | |
| US8026279 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8048917 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Nov, 2022
(3 years ago) | |
| US8114909 | AZURITY | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
Apr, 2026
(2 months from now) | |
| US8686034 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Jan, 2025
(11 months ago) | |
| US8795725 | AZURITY | GABA analog prodrug sustained release oral dosage forms |
Jun, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-652) | Jun 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
| Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage
HORIZANT family patents
47. Ingrezza patent expiration
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10851104 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(10 years from now) | |
| US10906902 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(10 years from now) | |
| US8039627 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Apr, 2031
(5 years from now) | |
| US10844058 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(10 years from now) | |
| US10851103 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(10 years from now) | |
| US10065952 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(10 years from now) | |
| US10919892 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(10 years from now) | |
| US10906903 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US11654142 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Nov, 2038
(12 years from now) | |
| US8357697 | NEUROCRINE | Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto |
Nov, 2027
(1 year, 9 months from now) | |
| US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US10940141 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2040
(14 years from now) | |
| US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US11026939 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(12 years from now) | |
| US11026931 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2039
(13 years from now) | |
| US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US11439629 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| US11311532 | NEUROCRINE | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
Sep, 2038
(12 years from now) | |
| US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2022 |
| New Indication(I-925) | Aug 18, 2026 |
| Orphan Drug Exclusivity(ODE-440) | Aug 18, 2030 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 11 April, 2021
Market Authorisation Date: 11 April, 2017
Dosage: CAPSULE
How can I launch a generic of INGREZZA before it's drug patent expiration?
More Information on Dosage
INGREZZA family patents
48. Inlyta patent expiration
Treatment: Treatment of renal cell carcinoma; In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-li...
INLYTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8791140 | PF PRISM CV | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
Dec, 2030
(4 years from now) | |
| US6534524 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Apr, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7141581 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Jun, 2020
(5 years ago) | |
| US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(9 years from now) | |
| US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(11 years from now) | |
|
US6534524 (Pediatric) | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Oct, 2025
(2 months ago) | |
|
US8791140 (Pediatric) | PF PRISM CV | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
Jun, 2031
(5 years from now) | |
|
US10869924 (Pediatric) | PF PRISM CV | PD-L1 antagonist combination treatments |
Jul, 2037
(11 years from now) | |
|
US10570202 (Pediatric) | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Aug, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2017 |
Drugs and Companies using AXITINIB ingredient
NCE-1 date: 28 January, 2016
Market Authorisation Date: 27 January, 2012
Dosage: TABLET
How can I launch a generic of INLYTA before it's drug patent expiration?
More Information on Dosage
INLYTA family patents
49. Invanz patent expiration
Treatment: Treatment of bacterial infectious disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5478820 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
May, 2016
(9 years ago) | |
| US5652233 | MSD SUB MERCK | Antibiotic compounds |
Feb, 2013
(12 years ago) | |
|
US5952323 (Pediatric) | MSD SUB MERCK | Carbapenem antibiotic |
Nov, 2017
(8 years ago) | |
| US7342005 | MSD SUB MERCK | Antibiotic compounds |
Feb, 2013
(12 years ago) | |
|
US7342005 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
Aug, 2013
(12 years ago) | |
|
US5652233 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
Aug, 2013
(12 years ago) | |
| US5478820 | MSD SUB MERCK | Antibiotic compounds |
Nov, 2015
(10 years ago) | |
| US5952323 | MSD SUB MERCK | Carbapenem antibiotic |
May, 2017
(8 years ago) | |
Drugs and Companies using ERTAPENEM SODIUM ingredient
Market Authorisation Date: 21 November, 2001
Dosage: INJECTABLE
How can I launch a generic of INVANZ before it's drug patent expiration?
More Information on Dosage
INVANZ family patents
50. Isturisa patent expiration
Treatment: Cushing's disease
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9434754 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(5 years from now) | |
| US8835646 | RECORDATI RARE | Organic compounds |
Aug, 2026
(7 months from now) | |
| US8314097 | RECORDATI RARE | Organic compounds |
Mar, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8609862 | RECORDATI RARE | Use of an adrenal hormone-modifying agent |
Jan, 2031
(5 years from now) | |
| US10709691 | RECORDATI RARE | Pharmaceutical dosage forms |
Oct, 2035
(9 years from now) | |
| US10143680 | RECORDATI RARE | Pharmaceutical dosage forms |
Jul, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 06, 2025 |
| Orphan Drug Exclusivity(ODE-286) | Mar 06, 2027 |
Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient
NCE-1 date: 06 March, 2024
Market Authorisation Date: 06 March, 2020
Dosage: TABLET
More Information on Dosage
ISTURISA family patents
51. Jesduvroq patent expiration
Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11643397 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(1 year, 5 months from now) | |
| US11117871 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(12 years from now) | |
| US8324208 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815884 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(1 year, 5 months from now) | |
| US8557834 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(1 year, 5 months from now) | |
| US11649217 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 01, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 01 February, 2027
Market Authorisation Date: 01 February, 2023
Dosage: TABLET
More Information on Dosage
JESDUVROQ family patents
52. Journavx patent expiration
Treatment: Treatment of moderate to severe acute pain in adults using suzetrigine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11834441 | VERTEX PHARMS INC | Substituted tetrahydrofurans as modulators of sodium channels |
Dec, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2030 |
Drugs and Companies using SUZETRIGINE ingredient
NCE-1 date: 30 January, 2029
Market Authorisation Date: 30 January, 2025
Dosage: TABLET
More Information on Dosage
JOURNAVX family patents
53. Keppra patent expiration
Treatment: NA
KEPPRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802142 | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Jun, 2031
(5 years from now) | |
|
US8802142 (Pediatric) | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Dec, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2014 |
| Pediatric Exclusivity(PED) | Jun 16, 2015 |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 06 January, 2006
Dosage: TABLET
How can I launch a generic of KEPPRA before it's drug patent expiration?
More Information on Dosage
KEPPRA family patents
54. Kerendia patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE49826 | BAYER HLTHCARE | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient |
Jul, 2035
(9 years from now) | |
| US8436180 | BAYER HLTHCARE | Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-279) | Sep 01, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 09, 2026 |
| New Indication(I-970) | Jul 11, 2028 |
| New Strength(NS) | Jul 11, 2028 |
Drugs and Companies using FINERENONE ingredient
NCE-1 date: 09 July, 2025
Market Authorisation Date: 09 July, 2021
Dosage: TABLET
More Information on Dosage
KERENDIA family patents
55. Korsuva patent expiration
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10793596 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 9 months from now) | |
| US7727963 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 9 months from now) | |
| US10017536 | VIFOR INTL | Synthetic peptide amides and dimers thereof |
Nov, 2027
(1 year, 9 months from now) | |
| US8536131 | VIFOR INTL | Synthetic peptide amides and dimers thereof |
Nov, 2027
(1 year, 9 months from now) | |
| US7713937 | VIFOR INTL | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(1 year, 9 months from now) | |
| US7402564 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10138270 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 9 months from now) | |
| US8486894 | VIFOR INTL | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(1 year, 9 months from now) | |
| US8217007 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 9 months from now) | |
| US9334305 | VIFOR INTL | Synthetic peptide amides and dimers thereof |
Nov, 2027
(1 year, 9 months from now) | |
| US9359399 | VIFOR INTL | Synthetic peptide amides |
Nov, 2027
(1 year, 9 months from now) | |
| US8236766 | VIFOR INTL | Uses of synthetic peptide amides |
Nov, 2027
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 23 August, 2025
Market Authorisation Date: 23 August, 2021
Dosage: SOLUTION
More Information on Dosage
KORSUVA family patents
56. Lenvima patent expiration
Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer; First-line treatment of patients with unresectable hepatocellular carcinoma (hcc) using dosage modifications for adverse ...
LENVIMA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7612208 | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Sep, 2026
(8 months from now) | |
| US7253286 | EISAI INC | Nitrogen-containing aromatic derivatives |
Oct, 2025
(2 months ago) | |
| US11186547 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(9 years from now) | |
| US10407393 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(9 years from now) | |
| US10259791 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006256 | EISAI INC | Antitumor agent for thyroid cancer |
Jul, 2027
(1 year, 6 months from now) | |
| US12226409 | EISAI INC | Treatment of hepatocellular carcinoma |
May, 2038
(12 years from now) | |
|
US7612208 (Pediatric) | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Mar, 2027
(1 year, 2 months from now) | |
| US12083112 | EISAI INC | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
Mar, 2036
(10 years from now) | |
|
US7253286 (Pediatric) | EISAI INC | Nitrogen-containing aromatic derivatives |
Apr, 2026
(3 months from now) | |
|
US9006256 (Pediatric) | EISAI INC | Antitumor agent for thyroid cancer |
Jan, 2028
(2 years from now) | |
|
US11090386 (Pediatric) | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Aug, 2036
(10 years from now) | |
|
US11186547 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(10 years from now) | |
|
US10407393 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(10 years from now) | |
|
US12226409 (Pediatric) | EISAI INC | Treatment of hepatocellular carcinoma |
Nov, 2038
(12 years from now) | |
|
US10259791 (Pediatric) | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Feb, 2036
(10 years from now) | |
|
US12508313 (Pediatric) | EISAI INC | NA |
Apr, 2031
(5 years from now) | |
|
US12083112 (Pediatric) | EISAI INC | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
Sep, 2036
(10 years from now) | |
| US12508313 | EISAI INC | NA |
Oct, 2030
(4 years from now) | |
| US11090386 | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Feb, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-734) | May 13, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
| New Indication(I-787) | Aug 15, 2021 |
| Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
| Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
| New Indication(I-807) | Sep 17, 2022 |
| M(M-269) | Jul 21, 2024 |
| New Indication(I-868) | Aug 10, 2024 |
| M(M-272) | Dec 19, 2024 |
| Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
| M(M-14) | Apr 03, 2027 |
| Pediatric Exclusivity(PED) | Oct 03, 2027 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 03 October, 2026
Market Authorisation Date: 13 February, 2015
Dosage: CAPSULE
How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage
LENVIMA family patents
57. Lokelma patent expiration
Treatment: Treatment of hyperkalemia in adults
LOKELMA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9592253 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(9 years from now) | |
| US10300087 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(9 years from now) | |
| US9913860 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(7 years from now) | |
| US10413569 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US10695365 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(7 years from now) | |
| US8877255 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Oct, 2033
(7 years from now) | |
| US11406662 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US8802152 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Apr, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6332985 | ASTRAZENECA | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions |
Mar, 2019
(6 years ago) | |
| US9861658 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US9844567 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US11738044 | ASTRAZENECA | Extended use zirconium silicate compositions and methods of use thereof |
Oct, 2035
(9 years from now) | |
| US8808750 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US10398730 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| US10335432 | ASTRAZENECA | Microporous zirconium silicate for the treatment of hyperkalemia |
Feb, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-261) | Apr 24, 2023 |
| New Chemical Entity Exclusivity(NCE) | May 18, 2023 |
Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient
NCE-1 date: 18 May, 2022
Market Authorisation Date: 18 May, 2018
Dosage: FOR SUSPENSION
How can I launch a generic of LOKELMA before it's drug patent expiration?
More Information on Dosage
LOKELMA family patents
58. Lunesta patent expiration
Treatment: Method of inducing a hypnotic or sedative effect in a human by administering eszopiclone
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6864257 | WAYLIS THERAP | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Aug, 2012
(13 years ago) | |
| US6444673 | WAYLIS THERAP | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Feb, 2014
(11 years ago) | |
|
US6444673 (Pediatric) | WAYLIS THERAP | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Aug, 2014
(11 years ago) | |
|
US6864257 (Pediatric) | WAYLIS THERAP | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Mar, 2013
(12 years ago) | |
|
US7381724 (Pediatric) | WAYLIS THERAP | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same |
Jul, 2012
(13 years ago) | |
|
US6319926 (Pediatric) | WAYLIS THERAP | Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Jul, 2012
(13 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Oct 10, 2015 |
| Pediatric Exclusivity(PED) | Apr 10, 2016 |
Drugs and Companies using ESZOPICLONE ingredient
Market Authorisation Date: 15 December, 2004
Dosage: TABLET
How can I launch a generic of LUNESTA before it's drug patent expiration?
More Information on Dosage
LUNESTA family patents
59. Lyrica patent expiration
Treatment: Management of fibromyalgia; Treatment of seizure disorder; Treatment of pain, including neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, postherpetic neuralgia, a...
LYRICA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(7 years ago) | |
| US6001876 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(7 years ago) | |
|
US6001876 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(6 years ago) | |
| US5563175 | UPJOHN | GABA and L-glutamic acid analogs for antiseizure treatment |
Oct, 2013
(12 years ago) | |
|
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(6 years ago) | |
|
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(6 years ago) | |
| USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-651) | Jun 20, 2015 |
| M(M-193) | Dec 22, 2019 |
| New Patient Population(NPP) | May 23, 2022 |
| Pediatric Exclusivity(PED) | Nov 23, 2022 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 30 December, 2004
Dosage: CAPSULE; SOLUTION
How can I launch a generic of LYRICA before it's drug patent expiration?
More Information on Dosage
LYRICA family patents
60. Myrbetriq patent expiration
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency; For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, a...
MYRBETRIQ's oppositions filed in EPO
MYRBETRIQ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6699503 | APGDI | Hydrogel-forming sustained-release preparation |
Sep, 2013
(12 years ago) | |
| US7750029 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Dec, 2023
(2 years ago) | |
| US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(2 years ago) | |
| USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(2 years ago) | |
|
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(3 years ago) | |
| US6562375 | APGDI | Stable pharmaceutical composition for oral use |
Aug, 2020
(5 years ago) | |
| US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(2 years ago) | |
| US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(2 years ago) | |
| US6346532 | APGDI | Amide derivatives or salts thereof |
Oct, 2018
(7 years ago) | |
| US11707451 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(3 years from now) | |
| US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(3 years from now) | |
| US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(2 years from now) | |
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 8 months ago) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 8 months ago) | |
|
US8835474 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(1 year, 8 months ago) | |
|
USRE44872 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(1 year, 8 months ago) | |
| US12097189 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(3 years from now) | |
| US12059409 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(3 years from now) | |
|
US8772315 (Pediatric) | APGDI | Pharmaceutical composition for treating overactive bladder |
Apr, 2029
(3 years from now) | |
|
US11707451 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(4 years from now) | |
|
US12097189 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(4 years from now) | |
|
US10842780 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(4 years from now) | |
|
US12059409 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
| New Indication(I-777) | Apr 27, 2021 |
| New Indication(I-855) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage
MYRBETRIQ family patents
61. Namenda patent expiration
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5061703 (Pediatric) | ALLERGAN | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(10 years ago) | |
| US5061703 | ALLERGAN | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(10 years ago) | |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 April, 2005
Dosage: SOLUTION
How can I launch a generic of NAMENDA before it's drug patent expiration?
More Information on Dosage
NAMENDA family patents
62. Namenda patent expiration
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(10 years ago) | |
| US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(10 years ago) | |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 October, 2003
Dosage: TABLET
How can I launch a generic of NAMENDA before it's drug patent expiration?
More Information on Dosage
NAMENDA family patents
63. Neupro patent expiration
Treatment: A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient; Treatment of r...
NEUPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6884434 | UCB INC | Transdermal therapeutic system which contains a d2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
Mar, 2021
(4 years ago) | |
| US8617591 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Jul, 2023
(2 years ago) | |
| US7413747 | UCB INC | Transdermal therapeutic system for treating Parkinsonism |
Mar, 2019
(6 years ago) | |
| US6699498 | UCB INC | Transdermal therapeutic systems having improved stability and their production |
Nov, 2020
(5 years ago) | |
| US8246979 | UCB INC | Transdermal delivery system for the administration of rotigotine |
Sep, 2027
(1 year, 7 months from now) | |
| US8246980 | UCB INC | Transdermal delivery system |
Nov, 2025
(a month ago) | |
| US10350174 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(4 years from now) | |
| US9925150 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Mar, 2032
(6 years from now) | |
| US10130589 | UCB INC | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
Dec, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 09, 2012 |
| New Indication(I-646) | Apr 02, 2015 |
| New Indication(I-647) | Apr 02, 2015 |
Drugs and Companies using ROTIGOTINE ingredient
NCE-1 date: 10 May, 2011
Market Authorisation Date: 09 May, 2007
Dosage: FILM, EXTENDED RELEASE
How can I launch a generic of NEUPRO before it's drug patent expiration?
More Information on Dosage
NEUPRO family patents
64. Nexavar patent expiration
Treatment: Treatment of carcinoma of the thyroid; Treatment of advanced renal cell carcinoma; Treatment of unresectable hepatocellular carcinoma; Treatment of unresectable hepatocellular carcinoma, advanced rena...
NEXAVAR's oppositions filed in EPO
NEXAVAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8877933 | BAYER HLTHCARE | Thermodynamically stable form of a tosylate salt |
Dec, 2027
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8124630 | BAYER HLTHCARE | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(6 years ago) | |
| US8618141 | BAYER HLTHCARE | Aryl ureas with angiogenesis inhibiting activity |
Feb, 2023
(2 years ago) | |
| US8841330 | BAYER HLTHCARE | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(6 years ago) | |
| US7897623 | BAYER HLTHCARE | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
Jan, 2020
(6 years ago) | |
| US7351834 | BAYER HLTHCARE | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(6 years ago) | |
| US7235576 | BAYER HLTHCARE | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jan, 2020
(6 years ago) | |
| US9737488 | BAYER HLTHCARE | Pharmaceutical composition for the treatment of cancer |
Sep, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 20, 2012 |
| New Indication(I-677) | Nov 22, 2016 |
| Orphan Drug Exclusivity(ODE-56) | Nov 22, 2020 |
Drugs and Companies using SORAFENIB TOSYLATE ingredient
Market Authorisation Date: 20 December, 2005
Dosage: TABLET
How can I launch a generic of NEXAVAR before it's drug patent expiration?
More Information on Dosage
NEXAVAR family patents
65. Nourianz patent expiration
Treatment: A method of reducing off time from l-dopa therapy, comprising administering, to a human patient with parkinson's disease, an effective amount of istradefylline, wherein the patient currently receives ...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(1 year, 2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7727994 | KYOWA KIRIN | Methods of treating patients suffering from movement disorders |
Jan, 2023
(2 years ago) | |
| US7727993 | KYOWA KIRIN | Administering adenosine A2A receptor antagonist to reduce or suppress side effects of parkinson's disease therapy |
Jan, 2028
(2 years from now) | |
| US8318201 | KYOWA KIRIN | Method of stabilizing diarylvinylene compound |
Sep, 2027
(1 year, 7 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Dosage: TABLET
More Information on Dosage
NOURIANZ family patents
66. Nuplazid patent expiration
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof; Trea...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6756393 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(4 years ago) | |
| US7115634 | ACADIA PHARMS INC | 4-aminopiperidine and their use as a medicine |
Oct, 2021
(4 years ago) | |
| US9296694 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(4 years ago) | |
| US6815458 | ACADIA PHARMS INC | Azacyclic compounds |
Mar, 2021
(4 years ago) | |
| US7858789 | ACADIA PHARMS INC | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec, 2020
(5 years ago) | |
| US8110574 | ACADIA PHARMS INC | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec, 2020
(5 years ago) | |
| US7732615 | ACADIA PHARMS INC | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Jun, 2028
(2 years from now) | |
| US7923564 | ACADIA PHARMS INC | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Sep, 2025
(3 months ago) | |
| US7601740 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Apr, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9765053 | ACADIA PHARMS INC | Methods of treatment using selective 5-HT2A inverse agonists |
Jul, 2022
(3 years ago) | |
| US10028944 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US10517860 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(11 years from now) | |
| US7659285 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Aug, 2026
(7 months from now) | |
| US10953000 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(11 years from now) | |
| US8921393 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US8618130 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US9566271 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 11 months ago) | |
| US10849891 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| US11452721 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| US10449185 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| US10646480 | ACADIA PHARMS INC | Formulations of pimavanserin |
Aug, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Dosage: CAPSULE; TABLET
How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage
NUPLAZID family patents
67. Nurtec Odt patent expiration
Treatment: Preventive treatment of episodic migraine in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8314117 | PFIZER | CGRP receptor antagonists |
Feb, 2034
(8 years from now) | |
| US8759372 | PFIZER | N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt |
Feb, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11083724 | PFIZER | Rimegepant for CGRP related disorders |
Mar, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-865) | May 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | Feb 27, 2025 |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
NCE-1 date: 28 February, 2024
Market Authorisation Date: 27 February, 2020
Dosage: TABLET, ORALLY DISINTEGRATING
More Information on Dosage
NURTEC ODT family patents
68. Omontys patent expiration
Treatment: Treatment of anemia due to chronic kidney disease
Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 8 months ago) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 8 months ago) | |
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 8 months ago) | |
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(1 year, 8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(4 months from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(4 months from now) | |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Dosage: SOLUTION
More Information on Dosage
OMONTYS family patents
69. Ongentys patent expiration
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease; Adjunctive treatment to levodopa/carbidopa in patients with parkinson’s disease experiencing off episodes; Adjunctive t...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9630955 | AMNEAL | Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor |
Dec, 2032
(6 years from now) | |
| US8168793 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
Apr, 2029
(3 years from now) | |
| US8907099 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
May, 2027
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357468 | AMNEAL | Medicaments for slowing Parkinson's disease |
May, 2035
(9 years from now) | |
| US9745290 | AMNEAL | Dosage regimen for COMT inhibitors |
Oct, 2027
(1 year, 8 months from now) | |
| US9550759 | AMNEAL | Nitrocatechol derivatives as COMT inhibitors |
Jul, 2026
(6 months from now) | |
| US8524746 | AMNEAL | Dosage regimen for COMT inhibitors |
Jul, 2029
(3 years from now) | |
| US10583130 | AMNEAL | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(4 years from now) | |
| US12129247 | AMNEAL | Administration regime for nitrocatechols |
Jan, 2032
(5 years from now) | |
| US10071085 | AMNEAL | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2025 |
Drugs and Companies using OPICAPONE ingredient
NCE-1 date: 24 April, 2024
Market Authorisation Date: 24 April, 2020
Dosage: CAPSULE
More Information on Dosage
ONGENTYS family patents
70. Onpattro patent expiration
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
ONPATTRO's oppositions filed in EPO
ONPATTRO IPR and PTAB Proceedings
Can you believe ONPATTRO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9567582 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8895721 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8895718 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8372968 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8362231 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US8552171 | ALNYLAM PHARMS INC | RNA sequence-specific mediators of RNA interference |
Mar, 2021
(4 years ago) | |
| US11079379 | ALNYLAM PHARMS INC | Methods of treating transthyretin (TTR) mediated amyloidosis |
Aug, 2035
(9 years from now) | |
| US10240152 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(3 years from now) | |
| US8168775 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Aug, 2032
(6 years from now) | |
| US8334373 | ALNYLAM PHARMS INC | Nuclease resistant double-stranded ribonucleic acid |
May, 2025
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9193753 | ALNYLAM PHARMS INC | RNA sequence-specific mediators of RNA interference |
Mar, 2021
(4 years ago) | |
| US8778902 | ALNYLAM PHARMS INC | RNA interference mediating small RNA molecules |
Mar, 2021
(4 years ago) | |
| US9943539 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(2 years ago) | |
| US9943538 | ALNYLAM PHARMS INC | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
Nov, 2023
(2 years ago) | |
| US8741866 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(3 years from now) | |
| US8802644 | ALNYLAM PHARMS INC | Lipid formulation |
Oct, 2030
(4 years from now) | |
| US8822668 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8158601 | ALNYLAM PHARMS INC | Lipid formulation |
Nov, 2030
(4 years from now) | |
| US9364435 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US9234196 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of transthyretin |
Oct, 2029
(3 years from now) | |
| US11141378 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8642076 | ALNYLAM PHARMS INC | Lipid containing formulations |
Oct, 2027
(1 year, 8 months from now) | |
| US8492359 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| US8058069 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| M(M-270) | Jan 13, 2026 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Dosage: SOLUTION
More Information on Dosage
ONPATTRO family patents
71. Ponvory patent expiration
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titratio...
PONVORY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9062014 | VANDA PHARMS INC | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(6 years from now) | |
| USRE43728 | VANDA PHARMS INC | Thiazolidin-4-one derivatives |
Nov, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12336980 | VANDA PHARMS INC | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(9 years from now) | |
| US9000018 | VANDA PHARMS INC | Thiazolidin-4-one-derivatives |
Nov, 2024
(1 year, 1 month ago) | |
| US8273779 | VANDA PHARMS INC | Thiazolidin 4-one derivatives |
Dec, 2025
(27 days ago) | |
| US10220023 | VANDA PHARMS INC | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(9 years from now) | |
| US11951097 | VANDA PHARMS INC | Methods of treating multiple sclerosis |
Oct, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Dosage: TABLET
More Information on Dosage
PONVORY family patents
72. Prialt patent expiration
Treatment: Treatment of pain; Analgesia; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5795864 | TERSERA | Stable omega conopetide formulations |
Jun, 2015
(10 years ago) | |
| US5364842 | TERSERA | Method of producing analgesia |
Dec, 2016
(9 years ago) | |
| US8653033 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 3 months ago) | |
| US9707270 | TERSERA | Method for administering ω-conopeptide |
Oct, 2024
(1 year, 3 months ago) | |
| US8765680 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 3 months ago) | |
Drugs and Companies using ZICONOTIDE ACETATE ingredient
Market Authorisation Date: 28 December, 2004
Dosage: INJECTABLE
More Information on Dosage
PRIALT family patents
73. Qalsody patent expiration
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults who have a mutation in the superoxide dismutase 1 (sod1) gene
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10385341 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10968453 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(9 years from now) | |
| US10669546 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 25, 2028 |
| Orphan Drug Exclusivity(ODE-432) | Apr 25, 2030 |
Drugs and Companies using TOFERSEN ingredient
NCE-1 date: 26 April, 2027
Market Authorisation Date: 25 April, 2023
Dosage: SOLUTION
More Information on Dosage
QALSODY family patents
74. Qelbree patent expiration
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
QELBREE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458143 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(3 years from now) | |
| US9603853 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(7 years from now) | |
| US12121523 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(3 years from now) | |
| US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(3 years from now) | |
| US9358204 | SUPERNUS PHARMS | Formulations of viloxazine |
Feb, 2033
(7 years from now) | |
| US9662338 | SUPERNUS PHARMS | Formulations of viloxazine |
Apr, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2026 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2025
Market Authorisation Date: 02 April, 2021
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
QELBREE family patents
75. Qulipta patent expiration
Treatment: Preventive treatment of migraine in adults; Preventive treatment of migraine in adults undergoing concurrent treatment with a strong cyp3a4 inhibitor; Preventive treatment of migraine in adults with s...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(5 years from now) | |
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(6 years from now) | |
| US9850246 | ABBVIE | Process for making CGRP receptor antagonists |
Mar, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12383545 | ABBVIE | NA |
Jun, 2039
(13 years from now) | |
| US12090148 | ABBVIE | Treatment of migraine |
Jul, 2041
(15 years from now) | |
| US12350259 | ABBVIE | NA |
Feb, 2043
(17 years from now) | |
| US12465598 | ABBVIE | NA |
Sep, 2042
(16 years from now) | |
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Dosage: TABLET
More Information on Dosage
QULIPTA family patents
76. Qutenza patent expiration
Treatment: Method of using capsaicin in combination with a gel composition for removal of capsaicin from a treatment area or unintended area
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263059 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US10869827 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US6239180 | AVERITAS | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
Nov, 2016
(9 years ago) | |
| US8889113 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US10463598 | AVERITAS | Compositions and kits for the removal of irritating compounds from bodily surfaces |
Sep, 2023
(2 years ago) | |
| US9226903 | AVERITAS | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer or the system and use of said back layer |
Dec, 2028
(2 years from now) | |
| US10034841 | AVERITAS | Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer |
Sep, 2025
(4 months ago) | |
| US8821920 | AVERITAS | Therapeutic patch for transdermal delivery of capsaicin |
Mar, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2014 |
| Orphan Drug Exclusivity(ODE) | Nov 16, 2016 |
| New Indication(I-838) | Jul 17, 2023 |
Drugs and Companies using CAPSAICIN ingredient
NCE-1 date: 16 November, 2013
Market Authorisation Date: 16 November, 2009
Dosage: PATCH
More Information on Dosage
QUTENZA family patents
77. Quviviq patent expiration
Treatment: Treatment of insomnia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9732075 | IDORSIA | Benzimidazole-proline derivatives |
Jun, 2033
(7 years from now) | |
| US9790208 | IDORSIA | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10023560 | IDORSIA | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2027 |
| M(M-200) | Sep 30, 2027 |
| M(M-310) | Sep 30, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: 07 April, 2026
Market Authorisation Date: 07 April, 2022
Dosage: TABLET
More Information on Dosage
QUVIVIQ family patents
78. Radicava patent expiration
Treatment: Treatment of amyotrophic lateral sclerosis (als)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6933310 | TANABE PHARMA | Therapeutic agent for amyotrophic lateral sclerosis (ALS) |
Nov, 2020
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 05, 2022 |
| Orphan Drug Exclusivity(ODE) | May 05, 2024 |
| ODE*(ODE*) | May 05, 2024 |
| Orphan Drug Exclusivity(ODE-144) | May 05, 2024 |
Drugs and Companies using EDARAVONE ingredient
NCE-1 date: 05 May, 2021
Market Authorisation Date: 05 May, 2017
Dosage: SOLUTION
More Information on Dosage
RADICAVA family patents
79. Rapaflo patent expiration
Treatment: Use in the treatment of the signs and symptoms of benign prostatic hyperplasia (bph)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6015819 | ABBVIE | Use of alpha-1C specific compounds to treat benign prostatic hyperplasia |
Nov, 2012
(13 years ago) | |
| US5387603 | ABBVIE | 1,5,7-trisubstituted indoline compounds and salts thereof |
Dec, 2018
(7 years ago) | |
| US5403847 | ABBVIE | Use of α1C specific compounds to treat benign prostatic hyperlasia |
Nov, 2012
(13 years ago) | |
| US5780485 | ABBVIE | Use of α1c specific compounds to treat benign prostatic hyperplasia |
Nov, 2012
(13 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2013 |
Drugs and Companies using SILODOSIN ingredient
NCE-1 date: 08 October, 2012
Market Authorisation Date: 08 October, 2008
Dosage: CAPSULE
How can I launch a generic of RAPAFLO before it's drug patent expiration?
More Information on Dosage
RAPAFLO family patents
80. Rapamune patent expiration
Treatment: Inhibiting transplant rejection using rapamycin (sirolimus)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5536729 | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2013
(12 years ago) | |
| US5100899 | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jul, 2013
(12 years ago) | |
| US5989591 | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2018
(7 years ago) | |
|
US5536729 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2014
(11 years ago) | |
|
US5100899 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jan, 2014
(12 years ago) | |
|
US5403833 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof |
Oct, 2012
(13 years ago) | |
|
US5989591 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-92) | May 28, 2022 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 15 September, 1999
Dosage: SOLUTION; TABLET
How can I launch a generic of RAPAMUNE before it's drug patent expiration?
More Information on Dosage
RAPAMUNE family patents
81. Relpax patent expiration
Treatment: Treatment of migraine with or without aura
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5545644 | UPJOHN | Indole derivatives |
Dec, 2016
(9 years ago) | |
| US6110940 | UPJOHN | Salts of an anti-migraine indole derivative |
Aug, 2017
(8 years ago) | |
Drugs and Companies using ELETRIPTAN HYDROBROMIDE ingredient
Market Authorisation Date: 26 December, 2002
Dosage: TABLET
How can I launch a generic of RELPAX before it's drug patent expiration?
More Information on Dosage
RELPAX family patents
82. Reyvow patent expiration
Treatment: Acute treatment of migraine; Acute treatment of migraine with or without aura in adults
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(11 years from now) | |
| US7423050 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Feb, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748459 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Mar, 2023
(2 years ago) | |
| US12257246 | ELI LILLY AND CO | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide |
Jul, 2030
(4 years from now) | |
| US12071423 | ELI LILLY AND CO | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate |
Jul, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 01 February, 2024
Market Authorisation Date: 31 January, 2020
Dosage: TABLET
More Information on Dosage
REYVOW family patents
83. Rivfloza patent expiration
Treatment: Method of treating primary hyperoxaluria type 1 (ph1)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11286488 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(12 years from now) | |
| US10738311 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| US11053502 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| US11359203 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| US11661604 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(12 years from now) | |
| US10351854 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 27, 2028 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-443) | Sep 29, 2030 |
Drugs and Companies using NEDOSIRAN SODIUM ingredient
NCE-1 date: 30 September, 2027
Market Authorisation Date: 29 September, 2023
Dosage: SOLUTION
More Information on Dosage
RIVFLOZA family patents
84. Rozerem patent expiration
Treatment: Method of treating a biological rhythm disorder, such as insomnia; Method of treating insomnia characterized by difficulty with sleep onset
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098866 | TAKEDA PHARMS USA | Pharmaceutical preparation containing copolyvidone |
Nov, 2021
(4 years ago) | |
| US6034239 | TAKEDA PHARMS USA | Tricyclic compounds, their production and use |
Jul, 2019
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Oct 20, 2011 |
Drugs and Companies using RAMELTEON ingredient
Market Authorisation Date: 22 July, 2005
Dosage: TABLET
How can I launch a generic of ROZEREM before it's drug patent expiration?
More Information on Dosage
ROZEREM family patents
85. Samsca patent expiration
Treatment: Method of treating hyponatremia
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8501730 | OTSUKA | Process for preparing benzazepine compounds or salts thereof |
Sep, 2026
(7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5753677 | OTSUKA | Benzoheterocyclic compounds |
May, 2015
(10 years ago) | |
| US5258510 | OTSUKA | Benzoheterocyclic compounds |
Nov, 2012
(13 years ago) | |
| US10905694 | OTSUKA | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
Apr, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 19, 2014 |
Drugs and Companies using TOLVAPTAN ingredient
NCE-1 date: 19 May, 2013
Market Authorisation Date: 19 May, 2009
Dosage: TABLET
How can I launch a generic of SAMSCA before it's drug patent expiration?
More Information on Dosage
SAMSCA family patents
86. Sensipar patent expiration
Treatment: Method of decreasing or reducing parathyroid hormone level; Method of modulating parathyroid hormone secretion; Method of treating hyperparathyroidism; Method of reducing serum ionized calcium level; ...
SENSIPAR's oppositions filed in EPO
SENSIPAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6031003 | AMGEN | Calcium receptor-active molecules |
Dec, 2016
(9 years ago) | |
| US6211244 | AMGEN | Calcium receptor-active compounds |
Oct, 2015
(10 years ago) | |
| US6011068 | AMGEN | Calcium receptor-active molecules |
Mar, 2018
(7 years ago) | |
| US6313146 | AMGEN | Calcium receptor-active molecules |
Dec, 2016
(9 years ago) | |
| US7829595 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(8 months from now) | |
| US9375405 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-634) | Feb 25, 2014 |
| M(M-101) | Feb 25, 2014 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2018 |
| Orphan Drug Exclusivity(ODE-8) | Feb 25, 2018 |
| M(M-200) | May 23, 2020 |
| Orphan Drug Exclusivity(ODE-78) | Nov 21, 2021 |
Drugs and Companies using CINACALCET HYDROCHLORIDE ingredient
Market Authorisation Date: 08 March, 2004
Dosage: TABLET
How can I launch a generic of SENSIPAR before it's drug patent expiration?
More Information on Dosage
SENSIPAR family patents
87. Skyclarys patent expiration
Treatment: Method of treating friedrich's ataxia by activating the nrf2 pathway which reduces oxidative stress; Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9701709 | BIOGEN US | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(7 years from now) | |
| US9670147 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(3 years from now) | |
| US8993640 | BIOGEN US | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(7 years from now) | |
| US8124799 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Dec, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11919838 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(3 years from now) | |
| US11091430 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
Apr, 2029
(3 years from now) | |
| US8440854 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-270) | Dec 20, 2027 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2028 |
| Orphan Drug Exclusivity(ODE-427) | Feb 28, 2030 |
Drugs and Companies using OMAVELOXOLONE ingredient
NCE-1 date: 28 February, 2027
Market Authorisation Date: 28 February, 2023
Dosage: CAPSULE
More Information on Dosage
SKYCLARYS family patents
88. Spinraza patent expiration
Treatment: Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; Treatment of spinal muscular atrophy; Treatment of type iii spinal muscular atrophy; Treatment of infantile-onset spin...
SPINRAZA's oppositions filed in EPO
Can you believe SPINRAZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6166197 | BIOGEN IDEC | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
Dec, 2017
(8 years ago) | |
| US7101993 | BIOGEN IDEC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(2 years ago) | |
| US8361977 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing |
Dec, 2030
(4 years from now) | |
| US7838657 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Jul, 2027
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6210892 | BIOGEN IDEC | Alteration of cellular behavior by antisense modulation of mRNA processing |
Oct, 2018
(7 years ago) | |
| US9926559 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jan, 2034
(7 years from now) | |
| US9717750 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jun, 2030
(4 years from now) | |
| US8110560 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(a month ago) | |
| US12013403 | BIOGEN IDEC | Compositions and methods for detection of SMN protein in a subject and treatment of a subject |
Mar, 2036
(10 years from now) | |
| US10266822 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(a month ago) | |
| US10436802 | BIOGEN IDEC | Methods for treating spinal muscular atrophy |
Sep, 2035
(9 years from now) | |
| US8980853 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Nov, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-226) | May 14, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
| Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Dosage: SOLUTION
More Information on Dosage
SPINRAZA family patents
89. Stendra patent expiration
Treatment: Treatment of erectile dysfunction
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6656935 | VIVUS LLC | Aromatic nitrogen-containing 6-membered cyclic compounds |
Apr, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7501409 | VIVUS LLC | Preparations for oral administration |
May, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 27, 2017 |
| New Dosing Schedule(D-140) | Sep 17, 2017 |
| M(M-282) | Oct 18, 2025 |
Drugs and Companies using AVANAFIL ingredient
NCE-1 date: 27 April, 2016
Market Authorisation Date: 27 April, 2012
Dosage: TABLET
How can I launch a generic of STENDRA before it's drug patent expiration?
More Information on Dosage
STENDRA family patents
90. Strattera patent expiration
Treatment: Treatment of attention-deficit hyperactivity disorder
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5658590 (Pediatric) | LILLY | Treatment of attention-deficit/hyperactivity disorder |
May, 2017
(8 years ago) | |
| US5658590 | LILLY | Treatment of attention-deficit/hyperactivity disorder |
Nov, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-78) | Jul 23, 2011 |
Drugs and Companies using ATOMOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 November, 2002
Dosage: CAPSULE
How can I launch a generic of STRATTERA before it's drug patent expiration?
More Information on Dosage
STRATTERA family patents
91. Sunosi patent expiration
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa); Treatment of excessive daytime sleepiness in a breast-feeding pa...
SUNOSI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12384743 | AXSOME MALTA | NA |
Nov, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440715 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2031
(5 years from now) | |
| US12209059 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US12390419 | AXSOME MALTA | NA |
Sep, 2037
(11 years from now) | |
| US12090126 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11753368 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US11998639 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US12263145 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US12036194 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US12318362 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US10959976 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US11969404 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11648232 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US12194016 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11865098 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US11839599 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US10940133 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11771666 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11850226 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11850227 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11850228 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11857528 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11986454 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US12005036 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US10512609 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US11779554 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US12102609 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US10351517 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US11560354 | AXSOME MALTA | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof |
Mar, 2039
(13 years from now) | |
| US11160779 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11771667 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US8877806 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| US12064411 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11793776 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US10912754 | AXSOME MALTA | Methods and compositions for treating excessive sleepiness |
Jun, 2038
(12 years from now) | |
| US10195151 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(11 years from now) | |
| US11839598 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US11872203 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11872204 | AXSOME MALTA | Methods of administering solriamfetol to lactating women |
Dec, 2042
(16 years from now) | |
| US11986455 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(14 years from now) | |
| US9604917 | AXSOME MALTA | Treatment of sleep-wake disorders |
Jun, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity(ODE-254) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 18 June, 2023
Market Authorisation Date: 17 June, 2019
Dosage: TABLET
How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage
SUNOSI family patents
92. Sutent patent expiration
Treatment: Treatment of protein kinase related disorders, such as gastrointestinal stromal tumors, renal cell carcinoma and advanced pancreatic neuroendocrine tumors, with sunitinib; Treatment of gastrointestina...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7125905 (Pediatric) | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Aug, 2021
(4 years ago) | |
|
US6573293 (Pediatric) | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Aug, 2021
(4 years ago) | |
|
US7211600 (Pediatric) | CPPI CV | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
Jun, 2021
(4 years ago) | |
| US6573293 | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Feb, 2021
(4 years ago) | |
| US7211600 | CPPI CV | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
Dec, 2020
(5 years ago) | |
| US7125905 | CPPI CV | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Feb, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-639) | May 20, 2014 |
| New Indication(I-755) | Nov 16, 2020 |
| Pediatric Exclusivity(PED) | May 16, 2021 |
Drugs and Companies using SUNITINIB MALATE ingredient
Market Authorisation Date: 26 January, 2006
Dosage: CAPSULE
How can I launch a generic of SUTENT before it's drug patent expiration?
More Information on Dosage
SUTENT family patents
93. Tecfidera patent expiration
Treatment: Method of treating multiple sclerosis; Method of treating an autoimmune disease selected from autoimmune polyarthritis and multiple sclerosis but not treating psoriatic arthritis; Method of treating r...
TECFIDERA's oppositions filed in EPO
TECFIDERA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320999 | BIOGEN INC | Dimethyl fumarate for the treatment of multiple sclerosis |
May, 2020
(5 years ago) | |
| US8759393 | BIOGEN INC | Utilization of dialkylfumarates |
Jul, 2018
(7 years ago) | |
| US8524773 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2018
(7 years ago) | |
| US7803840 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2018
(7 years ago) | |
| US7619001 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2018
(7 years ago) | |
| US6509376 | BIOGEN INC | Utilization of dialkyfumarates |
Oct, 2019
(6 years ago) | |
| US8399514 | BIOGEN INC | Treatment for multiple sclerosis |
Feb, 2028
(2 years from now) | |
| US11129806 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(9 years from now) | |
| US10994003 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(9 years from now) | |
| US11007166 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(9 years from now) | |
| US11007167 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(9 years from now) | |
| US11246850 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(9 years from now) | |
| US10555993 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(9 years from now) | |
| US10959972 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(9 years from now) | |
| US10391160 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2018 |
| M(M-260) | Feb 05, 2023 |
Drugs and Companies using DIMETHYL FUMARATE ingredient
NCE-1 date: 27 March, 2017
Market Authorisation Date: 27 March, 2013
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of TECFIDERA before it's drug patent expiration?
More Information on Dosage
TECFIDERA family patents
94. Tegsedi patent expiration
Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis
TEGSEDI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7015315 | AKCEA THERAPS | Gapped oligonucleotides |
Mar, 2023
(2 years ago) | |
| US7101993 | AKCEA THERAPS | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(2 years ago) | |
| US9061044 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(5 years from now) | |
| US8101743 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2025
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399774 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(5 years from now) | |
| US8697860 | AKCEA THERAPS | Diagnosis and treatment of disease |
Apr, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2023 |
| Orphan Drug Exclusivity(ODE-212) | Oct 05, 2025 |
Drugs and Companies using INOTERSEN SODIUM ingredient
NCE-1 date: 05 October, 2022
Market Authorisation Date: 05 October, 2018
Dosage: SOLUTION
More Information on Dosage
TEGSEDI family patents
95. Torisel patent expiration
Treatment: Method of treating metastatic papillary renal cell carcinoma with temsirolimus.
TORISEL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44768 | PF PRISM CV | Rapamycin hydroxyesters |
Feb, 2019
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5362718 | PF PRISM CV | Rapamycin hydroxyesters |
Apr, 2014
(11 years ago) | |
| US8722700 | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jul, 2023
(2 years ago) | |
|
USRE44768 (Pediatric) | PF PRISM CV | Rapamycin hydroxyesters |
Aug, 2019
(6 years ago) | |
| US8455539 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(2 years ago) | |
| US8299116 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(2 years ago) | |
|
US5362718 (Pediatric) | PF PRISM CV | Rapamycin hydroxyesters |
Oct, 2014
(11 years ago) | |
| US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(6 years from now) | |
|
US8455539 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(1 year, 11 months ago) | |
|
US8722700 (Pediatric) | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jan, 2024
(1 year, 11 months ago) | |
| US8026276 | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jan, 2026
(6 days from now) | |
|
US8299116 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(1 year, 11 months ago) | |
|
US8026276 (Pediatric) | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jul, 2026
(6 months from now) | |
|
US8791097 (Pediatric) | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
Nov, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-91) | Apr 26, 2013 |
| M(M-92) | Jul 09, 2013 |
| Pediatric Exclusivity(PED) | Jan 09, 2014 |
| Orphan Drug Exclusivity(ODE) | May 30, 2014 |
| M(M-61) | May 30, 2015 |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Dosage: SOLUTION
How can I launch a generic of TORISEL before it's drug patent expiration?
More Information on Dosage
TORISEL family patents
96. Toviaz patent expiration
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
TOVIAZ IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(3 years ago) | |
| US7384980 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US7985772 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US7855230 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
| US8338478 | PFIZER | Derivatives of 3,3-diphenylpropylamines |
May, 2019
(6 years ago) | |
|
US6858650 (Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(3 years ago) | |
| US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(1 year, 4 months from now) | |
| US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(1 year, 4 months from now) | |
| US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(1 year, 4 months from now) | |
|
US7807715 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(1 year, 10 months from now) | |
|
US8088398 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(1 year, 10 months from now) | |
|
US8501723 (Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(1 year, 10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2013 |
| New Indication(I-861) | Jun 17, 2024 |
| Pediatric Exclusivity(PED) | Dec 17, 2024 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
NCE-1 date: 18 December, 2023
Market Authorisation Date: 31 October, 2008
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TOVIAZ before it's drug patent expiration?
More Information on Dosage
TOVIAZ family patents
97. Trileptal patent expiration
Treatment: Method of treating seizures
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7037525 | NOVARTIS | Oxacarbazepine film-coated tablets |
Feb, 2018
(7 years ago) | |
|
US8119148 (Pediatric) | NOVARTIS | Suspension comprising oxcarbazepine |
Jun, 2021
(4 years ago) | |
|
US7037525 (Pediatric) | NOVARTIS | Oxacarbazepine film-coated tablets |
Aug, 2018
(7 years ago) | |
| US8119148 | NOVARTIS | Suspension comprising oxcarbazepine |
Dec, 2020
(5 years ago) | |
Drugs and Companies using OXCARBAZEPINE ingredient
Market Authorisation Date: 25 May, 2001
Dosage: SUSPENSION; TABLET
How can I launch a generic of TRILEPTAL before it's drug patent expiration?
More Information on Dosage
TRILEPTAL family patents
98. Ubrelvy patent expiration
Treatment: Acute treatment of migraine with or without aura in a patient with severe hepatic impairment; Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with or without au...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(6 years from now) | |
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(5 years from now) | |
| US8912210 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Dec, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11717515 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US9833448 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(5 years from now) | |
| US12329750 | ABBVIE | NA |
Dec, 2041
(15 years from now) | |
| US12194030 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US11857542 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US12220408 | ABBVIE | Treatment of migraine |
Jan, 2035
(9 years from now) | |
| US12458632 | ABBVIE | NA |
Jan, 2035
(9 years from now) | |
| US12070450 | ABBVIE | Treatment of migraine |
Dec, 2041
(15 years from now) | |
| US12168004 | ABBVIE | Treatment of migraine |
Jan, 2035
(9 years from now) | |
| US11925709 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(9 years from now) | |
| US12458633 | ABBVIE | NA |
Jan, 2035
(9 years from now) | |
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(9 years from now) | |
| US12310953 | ABBVIE | Pharmaceutical formulations for the treatment of migraine |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
99. Uroxatral patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6149940 | ADVANZ PHARMA | Tablet with controlled release of alfuzosine chlorhydrate |
Aug, 2017
(8 years ago) | |
|
US6149940 (Pediatric) | ADVANZ PHARMA | Tablet with controlled release of alfuzosine chlorhydrate |
Feb, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-97) | Dec 15, 2013 |
| Pediatric Exclusivity(PED) | Jun 15, 2014 |
Drugs and Companies using ALFUZOSIN HYDROCHLORIDE ingredient
Market Authorisation Date: 12 June, 2003
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of UROXATRAL before it's drug patent expiration?
More Information on Dosage
UROXATRAL family patents
100. Vafseo patent expiration
Treatment: Treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11065237 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(8 years from now) | |
| US8343952 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Aug, 2027
(1 year, 6 months from now) | |
| US7811595 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Mar, 2028
(2 years from now) | |
| USRE47437 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(1 year, 5 months from now) | |
| US9701636 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(8 years from now) | |
| US8598210 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(1 year, 5 months from now) | |
| US10149842 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857543 | AKEBIA | Compositions and methods for treating anemia |
Jun, 2034
(8 years from now) | |
| US11844756 | AKEBIA | Compositions and methods for treating anemia |
Mar, 2036
(10 years from now) | |
| US9987262 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(8 years from now) | |
| US8940773 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Jun, 2027
(1 year, 5 months from now) | |
| US8323671 | AKEBIA | Prolyl hydroxylase inhibitors and methods of use |
Apr, 2028
(2 years from now) | |
| US11324734 | AKEBIA | Compositions and methods for treating anemia |
Mar, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2029 |
Drugs and Companies using VADADUSTAT ingredient
NCE-1 date: 27 March, 2028
Market Authorisation Date: 27 March, 2024
Dosage: TABLET
More Information on Dosage
VAFSEO family patents
101. Veltassa patent expiration
Treatment: Treatment of hyperkalemia
VELTASSA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8337824 | VIFOR PHARMA | Linear polyol stabilized polyfluoroacrylate compositions |
May, 2030
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778324 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 9 months ago) | |
| US7556799 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Feb, 2025
(10 months ago) | |
| US8889115 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 9 months ago) | |
| US8216560 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2027
(1 year, 1 month from now) | |
| US9492476 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(7 years from now) | |
| US8287847 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 9 months ago) | |
| US8475780 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 9 months ago) | |
| US10485821 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 9 months ago) | |
| US9925212 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(7 years from now) | |
| US11123363 | VIFOR PHARMA | Potassium-binding agents for treating hypertension and hyperkalemia |
Oct, 2033
(7 years from now) | |
| US8147873 | VIFOR PHARMA | Methods and compositions for treatment of ion imbalances |
Jun, 2028
(2 years from now) | |
| US8282913 | VIFOR PHARMA | Ion binding polymers and uses thereof |
May, 2027
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
| New Patient Population(NPP) | Oct 02, 2026 |
| New Strength(NS) | Oct 02, 2026 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Dosage: POWDER
How can I launch a generic of VELTASSA before it's drug patent expiration?
More Information on Dosage
VELTASSA family patents
102. Vesicare patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6017927 | ASTELLAS | Quinuclidine derivatives and medicinal composition thereof |
Nov, 2018
(7 years ago) | |
|
US6017927 (Pediatric) | ASTELLAS | Quinuclidine derivatives and medicinal composition thereof |
May, 2019
(6 years ago) | |
Drugs and Companies using SOLIFENACIN SUCCINATE ingredient
Market Authorisation Date: 19 November, 2004
Dosage: TABLET
How can I launch a generic of VESICARE before it's drug patent expiration?
More Information on Dosage
VESICARE family patents
103. Viltepso patent expiration
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
VILTEPSO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10870676 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(5 years from now) | |
| US9079934 | NIPPON SHINYAKU | Antisense nucleic acids |
Apr, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 12, 2025 |
| Orphan Drug Exclusivity(ODE-280) | Aug 12, 2027 |
Drugs and Companies using VILTOLARSEN ingredient
NCE-1 date: 12 August, 2024
Market Authorisation Date: 12 August, 2020
Dosage: SOLUTION
More Information on Dosage
VILTEPSO family patents
104. Vimpat patent expiration
Treatment: Method of treating, as adjunctive therapy, partial-onset seizures in a patient with epilepsy aged 17 years and older; Method of treating, as adjunctive therapy, partial-onset seizures in a patient wit...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5654301 | UCB INC | Amino acid derivative anticonvulsant |
Aug, 2014
(11 years ago) | |
| USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2013 |
| New Dosing Schedule(D-143) | Aug 29, 2017 |
| New Dosing Schedule(D-144) | Aug 29, 2017 |
| New Indication(I-696) | Aug 29, 2017 |
| M(M-217) | Nov 03, 2020 |
| New Indication(I-878) | Nov 16, 2023 |
| New Patient Population(NPP) | Oct 14, 2024 |
| New Dosing Schedule(D-188) | Apr 28, 2026 |
Drugs and Companies using LACOSAMIDE ingredient
NCE-1 date: 28 October, 2012
Market Authorisation Date: 28 October, 2008
Dosage: TABLET; SOLUTION
How can I launch a generic of VIMPAT before it's drug patent expiration?
More Information on Dosage
VIMPAT family patents
105. Votrient patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114885 | NOVARTIS | Chemical compounds |
Dec, 2021
(4 years ago) | |
| US7262203 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Dec, 2021
(4 years ago) | |
| US7105530 | NOVARTIS | Pyrimidineamines as angiogenesis modulators |
Oct, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2014 |
| New Indication(I-649) | Apr 26, 2015 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-23) | Apr 26, 2019 |
Drugs and Companies using PAZOPANIB HYDROCHLORIDE ingredient
NCE-1 date: 19 October, 2013
Market Authorisation Date: 19 October, 2009
Dosage: TABLET
More Information on Dosage
VOTRIENT family patents
106. Vumerity patent expiration
Treatment: Method of treating multiple sclerosis
VUMERITY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10080733 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(7 years from now) | |
| US8669281 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Oct, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9090558 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(7 years from now) | |
Drugs and Companies using DIROXIMEL FUMARATE ingredient
Market Authorisation Date: 29 October, 2019
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of VUMERITY before it's drug patent expiration?
More Information on Dosage
VUMERITY family patents
107. Vyondys 53 patent expiration
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
VYONDYS 53's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9416361 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10227590 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US10968450 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US9024007 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US10421966 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| US9994851 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10533174 | SAREPTA THERAPS INC | Splice-region antisense composition and method |
May, 2021
(4 years ago) | |
| US10266827 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| USRE47691 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2028
(2 years from now) | |
| US10995337 | SAREPTA THERAPS INC | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
Jun, 2025
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2024 |
| Orphan Drug Exclusivity(ODE-280) | Dec 12, 2026 |
Drugs and Companies using GOLODIRSEN ingredient
NCE-1 date: 13 December, 2023
Market Authorisation Date: 12 December, 2019
Dosage: SOLUTION
More Information on Dosage
VYONDYS 53 family patents
108. Vyvanse patent expiration
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disorder (adhd) in adults; Indicated for the treatment of attention-deficit/hyperacti...
VYVANSE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7662787 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(2 years ago) | |
| US7659253 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7655630 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7671030 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7659254 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
|
US7662788 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
| US7713936 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
|
US7700561 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7723305 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
| US7659253 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7687467 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Apr, 2023
(2 years ago) | |
| US7723305 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7718619 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7671031 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7662788 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7678770 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(2 years ago) | |
| US7105486 | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Jun, 2023
(2 years ago) | |
| US7678771 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(2 years ago) | |
| US7674774 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Mar, 2023
(2 years ago) | |
| US7655630 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
|
US7671030 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7718619 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
| US7700561 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Jun, 2023
(2 years ago) | |
| US7687466 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(2 years ago) | |
| US7662787 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(2 years ago) | |
| US7223735 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Jun, 2023
(2 years ago) | |
|
US7662787 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(2 years ago) | |
|
US7671031 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7674774 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7713936 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7105486 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Aug, 2023
(2 years ago) | |
|
US7223735 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(2 years ago) | |
|
US7655630 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7659253 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7659254 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7678770 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7678771 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7687466 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
|
US7687467 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 23, 2012 |
| M(M-82) | Apr 05, 2013 |
| New Patient Population(NPP) | Nov 10, 2013 |
| New Indication(I-645) | Jan 31, 2015 |
| New Indication(I-703) | Jan 30, 2018 |
| M(M-188) | Oct 14, 2019 |
Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient
Market Authorisation Date: 28 January, 2017
Dosage: CAPSULE
How can I launch a generic of VYVANSE before it's drug patent expiration?
More Information on Dosage
VYVANSE family patents
109. Welireg patent expiration
Treatment: Treatment of adult patients with von hippel-lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not r...
Can you believe WELIREG received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE49948 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(8 years from now) | |
| US9969689 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(8 years from now) | |
| US9908845 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12358870 | MERCK SHARP DOHME | NA |
Jun, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2026 |
| New Indication(I-931) | Dec 14, 2026 |
| New Indication(I-968) | May 14, 2028 |
| Orphan Drug Exclusivity(ODE-364) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 13 August, 2025
Market Authorisation Date: 13 August, 2021
Dosage: TABLET
More Information on Dosage
WELIREG family patents
110. Xadago patent expiration
Treatment: Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8278485 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Jun, 2027
(1 year, 4 months from now) | |
| US8076515 | MDD US | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides |
Dec, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8283380 | MDD US | Methods for treatment of parkinson's disease |
Mar, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2022 |
Drugs and Companies using SAFINAMIDE MESYLATE ingredient
NCE-1 date: 21 March, 2021
Market Authorisation Date: 21 March, 2017
Dosage: TABLET
More Information on Dosage
XADAGO family patents
111. Xcopri patent expiration
Treatment: Co-administration of cenobamate with phenobarbital and/or phenytoin for the treatment of partial onset seizures
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598279 | SK LIFE | Neurotherapeutic azole compounds |
Oct, 2032
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654133 | SK LIFE | Use of [(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate in combination therapy |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2025 |
Drugs and Companies using CENOBAMATE ingredient
NCE-1 date: 10 March, 2024
Market Authorisation Date: 10 March, 2020
Dosage: TABLET
More Information on Dosage
XCOPRI family patents
112. Xyrem patent expiration
Treatment: Method of treating cataplexy in patients with narcolepsy; Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; Method of treating exce...
XYREM's oppositions filed in EPO
XYREM IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9539330 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
| US8952062 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
| US8589182 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(3 years ago) | |
| US8731963 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(3 years ago) | |
|
US8731963 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(2 years ago) | |
| US8263650 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
|
US6780889 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jan, 2021
(5 years ago) | |
|
US7262219 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jan, 2021
(5 years ago) | |
|
US7765107 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(1 year, 28 days ago) | |
|
US7895059 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(2 years ago) | |
|
US8457988 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(2 years ago) | |
| US7262219 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jul, 2020
(5 years ago) | |
|
US7765106 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(1 year, 28 days ago) | |
| US8859619 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
|
US8589182 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2023
(2 years ago) | |
|
US7851506 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
|
US8263650 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
|
US8324275 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
|
US8859619 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
|
US8952062 (Pediatric) | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jun, 2020
(5 years ago) | |
| US9539330 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
| US8457988 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(3 years ago) | |
| US8324275 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
| US7668730 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(1 year, 6 months ago) | |
|
US7668730 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(1 year, 28 days ago) | |
| US7895059 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(3 years ago) | |
| US7851506 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Dec, 2019
(6 years ago) | |
| US7765107 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(1 year, 6 months ago) | |
| US7765106 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(1 year, 6 months ago) | |
| US6780889 | JAZZ PHARMS | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
Jul, 2020
(5 years ago) | |
| US9486426 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US9050302 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US8772306 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US11986446 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US10213400 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US11253494 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
| US10864181 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(7 years from now) | |
|
US8772306 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
|
US9486426 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
|
US9050302 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
|
US11253494 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
|
US10213400 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
|
US10864181 (Pediatric) | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Sep, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Nov 18, 2012 |
| New Patient Population(NPP) | Oct 26, 2021 |
| Orphan Drug Exclusivity(ODE-231) | Oct 26, 2025 |
| Pediatric Exclusivity(PED) | Apr 26, 2026 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 17 July, 2002
Dosage: SOLUTION
How can I launch a generic of XYREM before it's drug patent expiration?
More Information on Dosage
XYREM family patents
113. Zavzpret patent expiration
Treatment: Administration of zavegepant for acute treatment of migraine with or without aura
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8481546 | PFIZER | CGRP receptor antagonist |
Oct, 2031
(5 years from now) | |
| US7220862 | PFIZER | Calcitonin gene related peptide receptor antagonists |
Jan, 2024
(1 year, 11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7314883 | PFIZER | Anti-migraine treatments |
Dec, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 09, 2028 |
Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2027
Market Authorisation Date: 09 March, 2023
Dosage: SPRAY, METERED
More Information on Dosage
ZAVZPRET family patents
114. Zemdri patent expiration
Treatment: Method of using plazomicin to treat bacterial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8383596 | CIPLA USA | Antibacterial aminoglycoside analogs |
Jun, 2032
(6 years from now) | |
| US9688711 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9266919 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| US8822424 | CIPLA USA | Antibacterial aminoglycoside analogs |
Nov, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 25, 2023 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 25, 2028 |
Drugs and Companies using PLAZOMICIN SULFATE ingredient
NCE-1 date: 26 June, 2027
Market Authorisation Date: 25 June, 2018
Dosage: SOLUTION
More Information on Dosage
ZEMDRI family patents
115. Zeposia patent expiration
Treatment: Treatment of moderately to severely active ulcerative colitis (uc) in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting dise...
ZEPOSIA's oppositions filed in EPO
Can you believe ZEPOSIA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8481573 | BRISTOL | Modulators of sphingosine phosphate receptors |
Mar, 2033
(7 years from now) | |
| US11680050 | BRISTOL | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
Sep, 2038
(12 years from now) | |
| US8796318 | BRISTOL | Modulators of sphingosine phosphate receptors |
May, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239846 | BRISTOL | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Nov, 2030
(4 years from now) | |
| US9382217 | BRISTOL | Modulators of sphingosine phosphate receptors |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-860) | May 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2025 |
| M(M-309) | Aug 30, 2027 |
Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient
NCE-1 date: 25 March, 2024
Market Authorisation Date: 25 March, 2020
Dosage: CAPSULE
More Information on Dosage
ZEPOSIA family patents
116. Zilbrysq patent expiration
Treatment: Treatment of generalized myasthenia gravis (gmg) in an adult patient who is anti-acetylcholine receptor (achr) antibody positive by subcutaneous administration of c5 complement inhibitor zilucoplan
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10208089 | UCB INC | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| US10106579 | UCB INC | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| US11014965 | UCB INC | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| US10435438 | UCB INC | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| US10562934 | UCB INC | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11752190 | UCB INC | Modulators of complement activity |
Jun, 2035
(9 years from now) | |
| US10835574 | UCB INC | Modulators of complement activity |
Jun, 2035
(9 years from now) | |
| US11965040 | UCB INC | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| US11535650 | UCB INC | Modulation of complement activity |
Jun, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 17, 2028 |
| Orphan Drug Exclusivity(ODE-446) | Oct 17, 2030 |
Drugs and Companies using ZILUCOPLAN SODIUM ingredient
NCE-1 date: 18 October, 2027
Market Authorisation Date: 17 October, 2023
Dosage: SOLUTION
More Information on Dosage
ZILBRYSQ family patents
117. Ztalmy patent expiration
Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older; Treatment of seizures associated with cyclin-dependent kina...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618087 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US12115169 | MARINUS | NA |
Sep, 2042
(16 years from now) | |
| US12268696 | MARINUS | NA |
Sep, 2042
(16 years from now) | |
| US12144801 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(11 years from now) | |
| US7858609 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US10603308 | MARINUS | Methods and compositions for treatment of epileptic disorders |
Aug, 2037
(11 years from now) | |
| US9056116 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US8022054 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US8367651 | MARINUS | Solid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US9029355 | MARINUS | Solid ganaxolone compositions and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| US8318714 | MARINUS | Liquid ganaxolone formulations and methods for the making and use thereof |
Nov, 2026
(10 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 01, 2027 |
| New Dosing Schedule(D-197) | Oct 16, 2028 |
| Orphan Drug Exclusivity(ODE-395) | Jun 01, 2029 |
Drugs and Companies using GANAXOLONE ingredient
NCE-1 date: 01 June, 2026
Market Authorisation Date: 01 June, 2022
Dosage: SUSPENSION
More Information on Dosage
ZTALMY family patents